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ABSTRACT

THE MECHANICAL PROPERTIES OF NON-FAILING
AND FAILING HUMAN MYOCARDIUM

Heart failure is a clinical syndrome that manifests when there are structural and
functional impairments to the heart that reduces the ability of the ventricles to fill
or eject blood. The syndrome affects ~6 million Americans and is responsible for
nearly 300,000 deaths annually. At the core of the syndrome are dysfunctional
sarcomeres, the machinery that drives cardiac contraction and relaxation. By
assessing the mechanical properties of human cardiac tissue, the information
provided in this dissertation will provide data that demonstrates how sarcomeric
dysfunction contributes to heart failure in the left and right ventricles. Additionally,
these data will supply information on how probable therapeutics impact the
mechanical properties of the heart and the clinical implications. Thus, the overall
objective of this project is to assess the mechanical properties of failing and nonfailing human myocardium while concomitantly studying the molecular
mechanisms contributing to heart failure and work towards therapy.

Mechanical experiments were performed with human cardiac samples obtained
from patients who were receiving heart transplants and from organ donors who

did not have a history of heart failure. Cardiac samples were homogenized and
chemically permeabilized (pores in the membrane). Multicellular preparations
from failing and non-failing hearts were attached between a force transducer and
a motor to determine the mechanical properties.

In the first study, we compared the mechanical properties of cardiac samples
from the right and left ventricles of non-failing and failing hearts, as well as
determined the relative phosphorylation levels of specific sarcomeric proteins.
The results show that in non-failing hearts, calcium sensitivity was higher in the
left ventricle, and in failing hearts, calcium sensitivity was higher in the right
ventricle. The shift in the pattern of the calcium sensitivity data from non-failing
samples to failing samples underpin a statistical interaction between heart failure
status and the ventricles of the heart for calcium sensitivity. This interaction
suggests that heart failure is altering the sensitivity of the myofilament to Ca 2+
differently in the right ventricle. The mechanical data also demonstrated that
heart failure significantly reduced isometric force and maximum power in both
ventricles. Biochemical assays suggest that the cause of the interaction observed
in the calcium sensitivity data is driven by the phosphorylation profile of
sarcomeric proteins.

We then determined the effects of two small molecules (omecamtiv mecarbil and
para-Nitroblebbistatin) on the mechanical properties of human myocardium. The
results of those studies demonstrate that omecamtiv mecarbil increases calcium

sensitivity and slows the rate of force development in a dose-dependent manner
without altering maximum isometric force. Conversely, para-Nitroblebbistatin
reduced isometric force, power, and calcium sensitivity without changing
shortening velocity or the rate of force development.

Lastly, we measured the effects of engineered troponins on the mechanical
function of failing tissue. The results show that troponin C and troponin I
designed to either increase or decrease calcium sensitivity can significantly
increase or decrease calcium sensitivity without altering maximum force,
shortening velocity or the rate of tension development.

The findings reported in this dissertation have revealed novel mechanical data
from non-failing and failing human cardiac tissue. These data present three
significant results. First, the right vs. left ventricular comparison data shows that
heart failure in humans reduces maximum force and power in both ventricles
equally while altering myofilament calcium sensitivity of the left and right
ventricles in different ways. The change in calcium sensitivity may reflect
ventricle specific post-translational modifications of sarcomeric proteins. Second,
the use of myosin modulators revealed that molecules like omecamtiv mecarbil
and para-Nitroblebbistatin that directly target myosin function can modify calcium
sensitivity and the rate of force development in human cardiac tissue. Third, the
engineered troponin study showed that engineered troponins C and I can alter
myofilament calcium sensitivity without affecting myosin kinetics. Clinically, the

results of the small molecules and engineered protein studies suggest that small
molecules and engineered proteins could potentially serve as therapy for patients
suffering from heart disease.

KEYWORDS: Right and left ventricles, human hearts, cardiac specific small
molecules, calcium sensitivity, sarcomere, engineered proteins
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CHAPTER 1
Introduction

1.1. The heart as two pumps
The normal mammalian heart is a muscular pump that is divided into four
chambers, two atria, and two ventricles. The heart can be viewed as two
separate pumps, the right pump consisting of the right atrium and right ventricle
(RV) and the left pump composed of the left atrium and left ventricle (LV). The
atriums sit atop the ventricles where they receive blood from the low-pressure
venous systems which then makes its way into the ventricles. The RV and LV
which are separated by the interventricular septum then ejects the blood into the
low pressure pulmonary and high-pressure systemic systems respectively. As a
result, the RV is a low-pressure pump, while the LV is a high-pressure pump.

The ability of the ventricles to generate adequate pressures to pump blood into
the pulmonary and systemic vasculature is derived from the capacity of individual
cardiomyocytes to produce force. There are a series of events that must take
place for a cardiomyocyte to contract and produce force (electrical stimuli, Ca 2+
induced Ca2+ release, etc.). However, at the fundamental level, it is the
shortening of sarcomeres that produces the pressure in the ventricles. Cardiac
muscle can enhance the amount of force/pressure each ventricle generates by
increasing sarcomere length. Sarcomere length in the heart increases
proportionally with preload (stretching of the ventricles because of increased enddiastolic volume). Higher preload not only stretch sarcomeres but also increase
1

stroke volume (volume of blood pumped per beat). The mechanism that
describes the heart’s ability to increase stroke volume and contractility (intrinsic
ability of the heart to contract independently of preload or afterload) in response
to an increase in preload is the Frank-Starling mechanism 1 (Fig 1.1).

The right and left pumps must eject similar stroke volumes (volume of blood
pumped per beat) while working against different afterloads (load/pressure
imposed on ventricles during ejection. Therefore, each ventricle must generate
different pressures to eject blood. It is assumed that the thinner RV produces
lower pressures in comparison to the thicker LV during systole solely because of
the differences in structure. While it is not debatable that the structure of the
ventricles contributes to the amount of pressure they can produce, variations in
the mechanical properties of individual cardiomyocytes could augment the
geometrical effects.

1.2. Right and left ventricular mechanics
Echocardiography and magnetic resonance imaging (MRI) are two techniques
used to measure the global mechanical function of the RV and LV. The
mechanical parameters commonly assessed by both methods are strain
(deformation of an object) and strain rate (strain per unit time) 2. Strain is
produced when stress (force per unit cross-sectional area) is applied to the walls
of the ventricles 3. Measuring strain and strain rate can be used to determine the
velocity of contraction and relaxation, and estimate the filling pressures of the

2

ventricles 4. MRI and echocardiographic measurements are important for
understanding global pump function. However, neither technique can be used to
measure mechanical properties at the cellular level.

To measure the mechanical properties of the RV and LV at the cellular level,
researchers have used either intact isolated cells, trabeculae, or papillary muscle
or permeabilized (single or multicellular preparations with holes in the
membrane) samples. With intact isolated single cells, an investigator uses a
high-speed camera to record the mechanical properties when the cell contracts
and relaxes. Whereas experiments using either intact trabeculae, papillary
muscle, or permeabilized samples utilize a force transducer and a motor. The
mechanical parameters that have been reported from isolated intact single cells
include time to peak contraction and relaxation, the rate of shortening and relengthening, and time to 50% or 90% relaxation. Studies that have used intact
trabeculae or papillary muscles have also reported mechanical parameters
similar to that reported in intact single cells, but have also recorded force/tension.

In permeabilized samples, cells are not living, as the membrane has been
skinned (perforated). However, the contractile structure is still in place, which will
contract when exposed to Ca2+. Permeabilized samples allow researchers to
measure contractile properties such as sensitivity of the myofilaments to Ca2+
and the rate of force development which cannot be assessed using intact

3

samples. Also, permeabilized samples can also be used to measure maximum
force, maximum shortening velocity, and power.

In animals, both intact and permeabilized tissue from the RV and LV have been
used to compare the mechanical properties of the ventricles

5-12.

In human 13,

only intact cells have been measured. Data from intact cells have conflicted,
whereas in permeabilized samples, the results have been more consistent.
However, the reports from permeabilized samples in animals have raised
questions as to whether mechanical differences exist in permeabilized samples
from humans, as the animal data from permeabilized tissue have revealed interventricular differences that are not measurable in intact cells. Thus, an
assessment of the mechanical properties of the RV and LV in intact and
permeabilized cells is needed to determine if mechanical differences exist
between the ventricles.

1.3. Right and left ventricular differences
The RV and LV of healthy mammalian hearts have different embryologic,
metabolic, structural, functional, and electrophysiological characteristics.
However, it is unclear if mechanical differences exist between the cells of the
ventricles of healthy hearts, and the subsequent effect of heart failure on the
contractile properties of both ventricles, as previous studies have reported
inconsistent findings.

4

1.3.1. Embryological origins
The embryological origins of RV and LV are different (Table 1.1

14).

During

gastrulation, cardiac progenitor cells emerge from the mesodermal layer

15.

The

cardiac progenitors that differentiate into the cardiomyocytes forming the LV
originate from the primary heart field (first population of cells to migrate to heartforming region), whereas progenitor cells that develop into the RV arise from the
secondary heart field (second set of cardiac progenitors to migrate into the heartforming region) 14-16. Consequently, there are differences in the genes that
regulate ventricular formation, such as the basic helix-loop-helix transcription
factors HAND1 & HAND2, which specifically regulate LV & RV formation
respectively 14-19.

1.3.2. Functional and structural differences
Under normal physiological conditions, the RV and LV generate different
pressures to pump the same volume of blood during each cardiac cycle (Table
1.1 14). The RV creates ~25 mm Hg to pump blood into the low resistance
pulmonary vasculature, while the LV produces ~120 mm Hg as it ejects blood
into the high resistance systemic circulation 14. Consequently, by virtue of
Laplace’s law, the low-pressure RV is thin walled and the high-pressure LV is
thick walled 20.

The shapes of the ventricles also vary (Table 1.1

14).

The LV has a prolate

ellipsoid shape, a contrast to the elaborate RV that is triangular when viewed
from the side and crescent shaped when viewed in cross-section 21,22.
5

Additionally, the ventricles show clear anatomical differences in myocardial
architecture. In the LV, cells in the mid-myocardium (middle layer) are arranged
circumferentially in the short-axis plane of the equator with fibers angles of 20° to
-20°, whereas the sub-epicardial (outermost layer) and sub-endocardial
(innermost layer) cells are layered obliquely and helically with fiber angles
ranging from 30° to 80° 14,21. As a result, the contraction of the LV is
circumferential and radial with added rotational and twisting motions 14.
Conversely, myocytes in the RV are arranged predominantly longitudinal,
creating the peristaltic contraction seen in the RV 22.

1.3.3. Metabolic and electrophysiological differences
The RV and LV pump the same stroke volume. However, because of the low
resistance of the pulmonary circulation, the stroke work of the RV is ~75% less
than that of the LV. As a result, the RV is not as metabolically active

20.

Electrophysiological differences between the RV and LV has been reported in
healthy mice 5,23, rats 24, dogs 25,26, and guinea pigs 27. In humans, differences
have been reported between the ventricles of diseased hearts28. However, the
nature of the electrophysiological difference varies amongst species. In rodents
(mice and rats), the action potential duration of the RV is shorter than the action
potential duration in the LV 5,29, while in larger mammals (dogs), the notch during
phase 1 of the action potential is smaller in LV compared to the RV

26.

In small

and larger animals, functional differences in the electrophysiological properties of

6

the RV and LV have mainly been the result of differential expression and activity
of K+ channels in the ventricles 30. In rats, Clark et al. 29 demonstrated that the
heterogeneity seen in the action potential waveforms between the RV and LV is
the result of the variance in the distribution of transient outward K + currents. In
larger dogs, Di Diego and colleagues 26 also showed that the primary reason for
the differences in the phase 1 notch between the RV and LV is because of higher
transient outward K+ currents in the RV. Kondo et al. 5 in mice went one step
further in that they not only showed that interventricular differences in K+ currents
exist, but they also demonstrated that mechanically cells from the RV and LV
differ as a result of electrophysiological variances.

1.3.4. Mechanical properties in the RV and LV
Studies that have compared the mechanical properties of non-failing RV and LV
have used intact and permeabilized cells from several different models (Table
1.2). In intact isolated single cells, the data are inconclusive. Reports from
healthy cats 12, and human 13 have shown that cells from both chambers behave
similarly. Conversely, studies using intact single cells from pigs 8 and mice 5 have
shown differences. In pigs, the RV shortened more than the LV, whereas, in
mice, cellular shortening was greater in the LV.

Mechanical data comparing the RV and LV using intact papillary muscles,
trabeculae, and permeabilized samples have been more consistent. For
example, in intact papillary muscles from dogs 9 and rats 11, force was similar in

7

both ventricles. Force was also similar between the RV and LV of intact
trabeculae 6 and permeabilized 7,10 tissues from rats. In addition to the
mechanical force data, the two studies that have compared the sensitivity of the
myofilaments to Ca2+ in rats have also been consistent in that they both showed
that the LV was more sensitive to Ca2+ in non-failing preparations. Furthermore,
studies using permeabilized samples demonstrated that heart failure had a
significant effect on the mechanical properties of the ventricles, which studies in
intact samples have also shown (Table 1.3). Thus, experiments using
permeabilized human myocardium from the RV and LV are needed to (1)
determine if the inter-ventricular differences observed in rats are also present in
human hearts, and (2) assess the impact of heart failure on the mechanical
properties of both chambers.

1.3.5. Right-sided and left-sided heart failure
Heart failure is a clinical syndrome that manifests when there are structural and
functional impairments to the heart that reduce the ability of the ventricles to fill or
eject blood 31. There are more than 23 million people worldwide who are affected
by the disease, of which, ~6 million are Americans

32,33.

The mortality rate for

heart failure is high, as ~50% of patients die within the first five years of diagnosis
34-36.

Patients who suffer from heart failure can have right-sided dysfunction, left-sided
dysfunction, or dysfunction in both ventricles. Clinically, RV dysfunction has been
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under-appreciated, as it was believed that RV failure was primarily a result of
impaired LV function 37,38. However, several studies have shown that left-sided
and right-sided heart failure can develop independently of each other

39-43.

These

are important findings because they imply that it might be useful to develop
chamber-specific therapies to help patients who have predominantly left or
mostly right-sided dysfunction. Data quantifying the mechanical properties of
cells from the RV and LV could be used to identify potential therapeutic targets.

1.4. Systolic dysfunction
Diastolic and systolic heart failure are the two most common forms of the
syndrome encountered in clinical practice

44.

These forms of heart failure are the

result of either diastolic (impaired ventricular relaxation, compliance or filling) or
systolic (impaired contractile or pump function) dysfunction. In comparison to a
normal heart, patients suffering from diastolic dysfunction had similar stroke
volume but reduced left ventricular relaxation and increased passive stiffness

45.

Consequently, these patients have increased pressures during diastole, which
can be represented by the pressure-volume loop as an upward shift during filling
(Fig 1.2 46). The hallmark of systolic dysfunction is a reduction in stroke
volume/ejection fraction (Fig 1.2 46), which leads to the inability of the heart to
supply enough blood to meet basal metabolic demands

47.

Studies have shown that patients who suffer from diastolic heart failure may not
experience systolic heart failure. For example, Baicu et al.

9

48 demonstrated

that

left ventricular systolic performance, function and contractility, in general,
remains normal in patients who have diastolic heart failure. However, patients
who have systolic heart failure almost certainly have diastolic heart failure as well
49.

As a result, patients suffering from systolic heart failure not only display

reduced stroke volume/ejection fraction, but they also exhibit increased filling
pressures (Fig.1.2 46). The principal mechanism responsible for systolic heart
failure is impaired contractile function 45,46. Thus, a lot of attention has been given
to understanding contractile proteins and ways to improve contractile function.

1.5. The sarcomere
The sarcomere is the basic unit of muscle. Each sarcomere is bound by two Zdiscs which enclose the thin (actin-containing) and thick (myosin-containing)
filaments (Fig. 1.3A 50). There are hundreds of proteins found in the sarcomere.
However, it is the proteins comprising the thick and thin filaments that drive
muscle contraction. The proteins directly involved in carrying out a muscle
contraction in the thin filament are, actin, the polymerized backbone,
tropomyosin, a filamentous protein that wraps around action monomers inhibiting
the interaction between actin and myosin, and the troponin complex (Fig. 1.3B
50).

The trimeric troponin complex consists of troponin C (cTnC), the Ca2+ binding

subunit, troponin T (cTnT), the subunit that binds the troponin complex to
tropomyosin, and troponin I (cTnI), the inhibitory subunit

10

51.

The thick filaments consist of the molecular motor myosin II and associated
proteins, including the cardiac modulatory protein myosin binding protein C
(cMyBP-C) 52 (Fig. 1.3B 50). Myosin has two heavy chains and four light chains.
The myosin heavy chains contain three regions, a head (also referred to as either
the motor domain, cross-bridge or subfragment 1 (S1)), a neck, and a tail 53. The
motor domain has the ATPase and the actin binding sites which respond to ATP
binding. Attached to the motor domain are essential (ELC) and regulatory (RLC)
light chains, which can alter the function of the cross-bridges 54.

1.5.1. Cross-bridge cycle
Muscle contracts when thick and thin filaments slide past each other

55.

The

process is initiated by an action potential which causes an increase in
intracellular Ca2+ through a process termed Ca2+-induced Ca2+-release 56. High
amounts of Ca2+ then binds to cTnC resulting in the conformational change of the
troponin complex. The structural alteration in the troponin complex then leads to
a shift in tropomyosin exposing binding sites on actin for myosin cross-bridges to
bind 57. The attachment of actin and myosin because of increased Ca 2+ sets the
stage for the thick and thin filaments to slide past each other and generate force
through the actions of the cross-bridges.

Lymn and Taylor first proposed the cross-bridge cycle in 1971

58.

It explains the

kinetic properties of the actin-myosin complex during a contraction
62).

59-61 (Fig.

The binding of myosin to actin in the presence of ATP initiates the cross-
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1.4

bridge cycle, which stimulates the ATPase in the cross-bridges 53. In the absence
of ATP, the actin-myosin interaction forms a strong (rigor) complex. Upon the
binding of ATP to the ATPase, cross-bridges briefly dissociate from actin and
then re-attaches through weak hydrostatic bonds (step 1). The hydrolysis of ATP
to ADP + Pi then causes a conformational shift in the heads of the cross-bridges
leaving the myosin heads in a pre-stroke position (step 2). This reaction (ATP to
ADP + Pi) primes the cross-bridges for re-attachment to actin in a more strongly
bound force-producing state (step 3). During the transition period where the
myosin-actin interaction goes from a weakly to a strongly bound state, inorganic
phosphate is released leaving ADP (weakly bound to strongly bound are
represented in figure 1. 4 62 as 3a for weakly bound and 3b for strongly bound).
The next step in the cycle is the force producing state, as the release of inorganic
phosphate causes a conformational shift of the heads of cross-bridges (~10 nm),
pulling actin filaments towards the center of the sarcomere, this is referred to as
the “power stroke” (step 4). The final step in the cycle (step 5 Fig. 1.4

62)

is the

release of ADP which leaves cross-bridges and actin in a rigor state until the next
ATP molecule binds starting the cycle again.

The weakly to the strongly bound transition period of the cross-bridge cycle
(steps 3a and 3b in Fig. 1.4 62) is of great importance, as it serves as a molecular
target for therapy for patients suffering from heart conditions. Studies have
shown that this transition period can be altered with drugs. For examples, reports
in dogs 63 and rats 64 show that the cardiac myosin activator omecamtiv mecarbil

12

increased the rate of inorganic phosphate release which forces cross-bridges into
the strongly bound force-producing state faster. Conversely, Blebbistatin a small
molecule that inhibits myosin II function has been shown to slow down the
release of inorganic phosphate during the weakly to strongly bound transition
state, trapping cross-bridges in weakly bound state longer 65-68. The use of these
compounds or similar molecules may serve as therapy for patients suffering from
systolic heart failure, or hypertrophic (hypercontractility) cardiomyopathy
respectively.

The use of small molecules to modulate the cross-bridge cycle to improve
cardiac function may serve as a plausible option for patients suffering from
cardiac diseases. However, some cardiomyopathies are the result of mutations in
contractile proteins. Therefore, small molecules may not be beneficial to these
patients. Another area of research that has proved a therapeutic option for
patients suffering from cardiac disease is gene therapy. Thus, there is ongoing
research trying to devise ways to alter the contractile function of the heart by
modifying sarcomeric proteins. The modifications that are made to these proteins
are then used to replace dysfunctional proteins or change the phosphorylation
status of a particular sarcomeric protein to improve cardiac function.

1.5.2. Phosphorylation of myofilament proteins
The heart must continually adapt to changes in hemodynamic load as well as
respond to neurohumoral stresses on a beat-to-beat basis. To handle the
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constant changes, dynamic regulation of contractile apparatus is needed. Posttranslational modification of sarcomeric proteins is a primary mechanism for
altering cardiac function on a beat-to-beat basis 69,70. One of the most studied
post-translational modifications is phosphorylation

71.

In the sarcomere, studies

have shown that phosphorylation of thin and thick filament proteins can promote
or depress cross-bridge kinetics 72,73. Additionally, alteration in contractile protein
structure and function by post-translational modifications have been implicated in
heart failure 74,75.

There are several known kinases (ex. Serine/Threonine kinases such as protein
kinases A, C, D, G, & Ca2+/calmodulin protein kinase II) and phosphatases (ex.
protein phosphatase I) that modulate contractile protein function 76. The known
targets of these kinases and phosphatases are cTnI, cTnT, and tropomyosin in
the thin filament, 77-79 and MyBP-C and RLC in the thick filament 80-83. Stimulation
of the α and β adrenergic receptors on cardiomyocytes can enhance or reduce
contractile protein phosphorylation by augmenting or decreasing kinase or
phosphatase activity 84. One of the most studied pathways that are used to alter
kinase activity in the heart is the β-adrenergic pathway. At the contractile protein
level, β-adrenergic stimulation has been shown to enhance PKA levels which
phosphorylate several contractile proteins including cTnI.

The phosphorylation of cTnI is of importance in the forthcoming chapters, as
phosphorylation of this protein is known to alter myofilament Ca2+ sensitivity 85, a
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mechanical parameter measured in these studies. In chapter 5, the effects of
engineered cTnI and cTnC on Ca2+ sensitivity are discussed.
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1.6. Overall objective
The overall aim of this project is to assess the mechanical properties of failing
and non-failing human myocardium while concomitantly studying the molecular
mechanisms contributing to heart failure and work towards therapy.

1.6.1. Compare the mechanical properties of the RV and LV of non-failing
and failing human hearts. (Chapter 2)
Hypothesis: Myocardium from the RV and LV of human hearts has different
mechanical properties.
Rationale: The RV and LV of human hearts have different embryologic,
metabolic, structural, functional, and electrophysiological characteristics.
However, it is unclear if mechanical differences exist between the chambers in
non-failing and failing hearts.

1.6.2. Determine the effects of omecamtiv mecarbil on the mechanical
properties of failing human hearts. (Chapter 3)
Hypothesis: The cardiac myosin activator omecamtiv mecarbil will augment
mechanical force.
Rationale: Omecamtiv mecarbil is a drug design to enhance the rate of inorganic
phosphate release in the actin-myosin cycle. By increasing the rate of phosphate
release, the molecule increases the number of myosin heads strongly bound to
actin at any given time during the cross-bridge cycle. Thus, cardiac tissue
incubated with the drug should produce higher mechanical forces.
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1.6.3. Assess the effects of para-Nitroblebbistatin on the mechanical
properties of failing human hearts. (Chapter 4)
Hypothesis: Para-Nitroblebbistatin will decrease the maximum force and calcium
sensitivity in human cardiac samples incubated with the molecule.
Rationale: para-Nitroblebbistatin is a molecule designed to keep cross-bridges in
the weakly bound state with actin. Therefore, failing tissue incubated with the
molecule should produce less force and have lower calcium sensitivity as a result
of the molecule reducing the duty ratio (number of myosin heads in strong force
generating state).

1.6.4. Examine the effects of engineered proteins on the mechanical
properties of failing human myocardium. (Chapter 5)
Hypothesis: Cardiac troponins C and I engineered to increase or decrease Ca 2+
sensitivity will alter pCa50.
Rationale: The effects of engineered troponins C and I have been demonstrated
in vivo in rodent myocardium. However, how these proteins change the
mechanical properties of human samples is not known. By showing similar
effects in human hearts, engineered troponins C & I may serve as therapy for
patients suffering heart failure.
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Figure 1.1. The Frank-Starling mechanism
Curves represent a change in stroke volume in response to increasing preload.
Red line (heart failure), blue (normal healthy hearts), green (when contractility is
increased in the heart).
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Table 1.1. Differences between the left and right ventricles under normal conditions
Left ventricle

Right ventricle

Embryological origin

Primary heart field

Secondary heart field

Morphological
characteristics

Bullet shape; prolate ellipsoid

Complex, crescentic

Myocardial characteristics

Thick smooth walls; fine
trabeculations

Thin, heavily trabeculated
walls

Myocardial architecture

Predominant radial myocyte
orientation in the mid layers;
subendocardial myocytes follow
right-hand helix configuration;
subepicardial myocytes form lefthand helix

Predominant longitudinal
myocyte orientation;
angulated intrusion of
superficial myocytes toward
the endocardium

Physiological pump
conditions

High-resistance, high-pressure
pump; dominant radial thickening
and contraction during ejection

Low-resistance, lowcapacitance pump;
peristaltic-like motion from
inflow to outflow during
ejection

Flow characteristics

Well-defined isovolumic
contraction and relaxation; no
hangout period
Table modified from Friedberg & Redington, 201414
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No or minimal isovolumic
periods; hangout period

Table 1.2. Non-failing mechanical properties in the RV and LV reported in the literature
Model (Intact
NonMechanical
Non-failing
RV vs. LV
cells/trabeculae/papillary
failing
property
RV
comparison
muscle/permeabilized)
LV
Cats (intact cells)12
0.67 ± 0.19
Not significant
Rate of shortening
0.67 ±
(resting lengths/s)
0.12

Dogs (papillary muscle)9

Pigs (intact cells)8

Rate of relaxation
(resting lengths/s)

0.69 ± 0.22

0.69 ±
0.18

Not significant

Extent of
contraction (% of
resting length)

10.6 ± 2.6

10.6 ± 1.5

Not significant

Total tension
(g/mm2)

7.2 ± 1.6

7.9 ± 1.7

Not significant

Maximum rate of
tension
development
(mm2/g/s)

31.8 ± 8

28 ± 4

Not significant

Time to peak
tension (ms)

336 ± 26

401 ± 42

Significant
difference
(p<0.005) RV
reached peak
tension faster

Percent shortening
(%)

5.7 ± 0.2

4.6 ± 0.1

Significant
difference
(p<0.05) RV
shortened
more

Velocity of
shortening (µm/s)

87 ± 4

50 ± 1

Significant
difference
(p<0.05) RV
shortened
faster

Velocity of relengthening (µm/s)

80 ± 4

50 ± 1

Significant
difference
(p<0.05) RV
re-lengthened
faster

Time to peak
contraction (ms)

200 ± 4

247 ± 4

Significant
difference
(p<0.05) RV
contracted
faster

Time to 50%
relaxation (ms)

98 ± 3

101 ± 2

Not significant
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Rats (papillary muscle)11

Time to peak force
(ms)

130 ± 3

151 ± 4

Active force
(g/mm2)

6.0 ± 0.4

6.2 ± 04

Significant
difference
(p<0.01) RV
reached peak
force faster
Not significant

Maximum rate of
force development
(g/mm2/s)

74 ± 6

70 ± 4

Not significant

Maximum
shortening (%)

18 ± 1

13 ± 0.5

Significant
difference
(p<0.05) RV
shortened
more

Maximum
shortening velocity
(muscle lengths/s)

1.98 ± 0.14

1.13 ±
0.07

Significant
difference
(p<0.05) RV
shortened
faster

Rats (trabeculae)6

Force (mN/mm2)

Values not
presented
(figure)

Values not
presented
(figure)

Not significant

Mice (intact cells)5

Sarcomere length
shortening (µm)

0.033 ±
0.003

0.041 ±
0.003

Significant
difference
(p<0.01) LV
shortened
more

Rise time (50% to
peak, ms)

54.7 ± 1

51 ± 1

Not significant

Decay time (50% to
baseline, ms)

117 ± 5

98 ± 3

Significant
difference
(p<0.01) LV
decay faster

Time to peak
shortening (s)

Values not
presented
(figure)

Values not
presented
(figure)

Not significant

Time to relaxation
(s)

Values not
presented
(figure)

Values not
Presented
(figure)

Not significant

Maximum force
(mN/mm2)

28.1 ± 1.7

26.7 ± 1.3

Not significant

Human (intact cells)13

Rats (Permeabilized
cells)7
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Rats (Permeabilized
strips)10

EC50 (µmol/L) (

1.77 ± 0.01

1.36 ±
0.06

Significant
difference
(p<0.05) LV
more sensitive
to Ca2+

Maximum force
(mN/mm2)
pCa50

0.85 ± 0.15

1.5 ± 0.25

Not significant

5.7 ± 0.09

6.0 ± 0.05

Significant
difference
(p<0.05) LV
more sensitive
to Ca2+
2+
*EC50 & pCa50 indicates the Ca concentration at 50% of maximum force, and is the index for
myofilament Ca2+ sensitivity.
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Table 1.3. Comparison of non-failing and failing RV and LV mechanical properties
reported in the literature
Model (Intact
Mechanic NonNonNon-failing RV &
Failing Failing
cells/trabeculae
al
failing
failing
LV vs. Failing RV
RV
LV
/permeabilized)
property
RV
LV
& LV
Pigs (intact
Percent
5.7 ±
4.6 ±
3.1 ±
2.3 ±
Significant
cells)8
shortening 0.2
0.1
0.1
0.1
difference
(%)
(p<0.05) Failing
RV & LV
shortened less
than non-failing
RV & LV. Failing
LV shortened less
than failing RV

Rats
(trabeculae)6

Velocity of
shortening
(µm/s)

87 ± 4

50 ± 1

48 ± 2

33 ± 1

Significant
difference
(p<0.05) Failing
RV & LV velocity
of shortening was
slower than Nonfailing RV & LV.
Failing LV velocity
of shortening was
slower than failing
RV

Velocity of
relengthenin
g (µm/s)

80 ± 4

50 ± 1

50 ± 3

32 ± 1

Significant
difference
(p<0.05) Failing
RV & LV relengthened
slower. Failing LV
re-lengthened
slower than failing
RV

Time to
peak
contractio
n (ms)

200 ± 4

247 ± 4

242 ± 4

234 ± 4

Significant
difference
(p<0.05) Failing
RV took longer to
get to peak
contraction, and
failing LV got to
peak contraction
faster than nonfailing LV

Time to
50%
relaxation
(ms)
Force
(mN/mm2)

98 ± 3

101 ± 2

102 ± 3

105 ± 3

Not significant

Values
not
present

Values
not
present

Values
not
present

Values
not
present

Not significant
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Human (intact
cells)13

Rats
(Permeabilized
cells)7

Rats
(Permeabilized
strips)10

ed
(figure)

ed
(figure)

ed
(figure)

ed
(figure)

Time to
peak
shortening
(s)

Values
not
present
ed
(figure)

Values
not
present
ed
(figure)

Values
not
present
ed
(figure)

Values
not
present
ed
(figure)

Not significant

Time to
relaxation
(s)

Values
not
present
ed
(figure)

Values
not
Present
ed
(figure)

Values
not
present
ed
(figure)

Values
not
Present
ed
(figure)

Not significant

Maximum
force
(mN/mm2)

28.1 ±
1.7

26.7 ±
1.3

14.9 ±
1.0

13.3 ±
0.8

Significant
difference
(p<0.05) Failing
RV & LV produced
less force

EC50
(µmol/L)

1.77 ±
0.01

1.36 ±
0.06

1.59 ±
0.08

2.42 ±
0.18

Significant
difference
(p<0.05) Nonfailing LV is more
sensitive to Ca2+
than failing LV

Maximum
force
(mN/mm2)

0.85 ±
0.15

1.5 ±
0.25

1.7 ±
0.35

1.7 ±
0.27

Significant
difference
(p<0.05) Failing
RV produce more
force than nonfailing RV

5.7 ±
0.09

6.0 ±
0.05

6.0 ±
0.09

6.0 ±
0.09

Significant
difference
(p<0.05) Failing
RV is more
sensitive to Ca2+
than non-failing
RV.
*EC50 & pCa50 indicates the Ca2+ concentration at 50% of the maximum force and is the index for
myofilament Ca2+ sensitivity.
pCa50
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Figure 1.2. Left Ventricular Pressure-Volume Loops in Systolic and
Diastolic Dysfunction
A) Systolic dysfunction with decreased stroke volume, black line displaced
downward. B) Normal pressure-volume loop. C) Diastolic dysfunction, the
diastolic pressure has shifted up (solid curved black line). (Modified from
Aurigemma and Gaasch, 2004 46)
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Figure 1.3. Sarcomere
A) Schematic of sarcomere bounded by two Z-disc with thick and thin filaments.
B) Close up of selected thin and thick filament proteins. Thin filament proteins:
actin, tropomyosin (TM), troponin C (TnC), troponin T (TnT), troponin I (TnI);
thick filament proteins: SI subfragment/cross-bridges (S1), myosin binding
protein C (MyBP-C), regulatory light chain (RLC), essential light chain (ELC),
lever arm (S2), light meromyosin (LMM). (Modified from Hwang and Sykes, 2015
50)
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Figure 1.4. Actin-myosin cross-bridge cycle
Yellow cross-bridges represent actin and myosin in the weakly bound state; red
cross-bridges represent actin and myosin in the strongly bound state. Step 1:
Binding of ATP to cross-bridge dissociates myosin heads from actin. Step 2:
Hydrolysis of ATP to ADP + Pi locking myosin heads in pre-stroke configuration.
Step 3 (a and b): Transition of actin-myosin interaction from weakly bounded to
strong binding, which results from the release of inorganic phosphate. Step 4:
Powerstroke, cross-bridges shift ~10-nm pulling actin to the center of the
sarcomere. Step 5: ADP released, actin and myosin remain in rigor until new
ATP binds. (Adapted from James Spudich, 2014
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62)

Chapter 2
The Ca2+ sensitivity of right ventricular myocardium increases more than
the Ca2+ sensitivity of left ventricular myocardium in human heart failure

2.1. Introduction
In healthy human hearts, the left ventricle (LV) is a thick-walled bullet shaped
chamber that generates high pressure (~120 mm Hg during systole) to pump
blood around the systemic circulation. Conversely, the right ventricle (RV) is a
thinner crescent shaped low-pressure pump that produces ~25 mm Hg as it
ejects blood into the pulmonary vasculature

5,14.

While it is clear that the distinct

chamber structures contribute to the inter-ventricular difference in systolic
pressure, it is not known if variation in myocardial contractile properties
augments the geometrical effects. Neither is it known whether heart failure
affects cells from the LV and the RV in the same way.

The impact of heart failure on LV myocardial function has been reported
extensively. Studies using skinned cardiac samples from patients with end-stage
heart failure have shown that the failing heart is more sensitive to Ca 2+ and
develops less contractile force than samples obtained from organ donors who did
not have heart failure 86-93. However, it is less clear how heart failure alters the
contractile properties of tissue from the RV.

Previous reports that have looked at the effects of heart failure on maximal force
(Fmax) and Ca2+ sensitivity (pCa50) in the RV and LV have used animal models.
28

Belin et al. 7 demonstrated that heart failure in rats reduced Fmax in permeabilized
myocytes from both ventricles. Conversely, Perreault and colleagues

10 showed

that heart failure increased Fmax in the RV and had no effect on the LV. Both
studies revealed that non-failing cells from the LV are more sensitive to Ca2+ than
non-failing cells from the RV. In failing tissue, Perreault et al.

10 found

that heart

failure increased pCa50 in the RV but not in the LV, while Belin et al. 7 reported
that heart failure reduced pCa50 in the LV without altering pCa50 in the RV.

The data reported in this manuscript extend these studies to human myocardium.
Our results show that pCa50 values measured for multicellular preparations from
non-failing LV were greater than pCa50 values measured for non-failing RV
specimens. In failing hearts, the opposite was true. Failing RV samples had
higher pCa50 values than failing LV samples. Data quantifying the relative
phosphorylation levels of myofilament proteins suggested that the shifts in Ca2+
sensitivity reflected changes in the relative phosphorylation of cardiac troponin I
(cTnI). There were no inter-ventricular differences in maximum force, maximum
power output or maximum shortening velocity.

2.2. Materials and Methods
2.2.1. Procurement of human samples
The human cardiac samples used in this study were acquired using the collection
protocol described by Blair et al. 94. Briefly, hearts procured from patients
undergoing cardiac transplants at the University of Kentucky and from organ
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donors who did not have heart failure were given to a researcher immediately
after being removed from the patient. The samples were obtained from throughwall sections cut from the distal region of the LV and RV. The LV samples were
then further dissected transmurally, forming sub-epicardial, mid-myocardial, and
sub-endocardial specimens. RV samples were not separated transmurally, as the
RV wall is typically thinner and the dissection is harder to perform consistently.
The specimens were snap-frozen in liquid nitrogen within 30 minutes of being
removed from the patient and stored in the vapor phase of liquid nitrogen
at -150°C until use. The University of Kentucky Institutional Review Board
approved all procedures, and subjects gave informed consent.
Previous data from our laboratory 95 showed that heart failure has a greater
impact on the contractile properties of samples from the middle transmural region
of the LV than on samples from the LV sub-epicardium or LV sub-endocardium.
This study compared samples from the RV and the mid-myocardium of the LV to
optimize the probability of detecting statistically significant effects.

2.2.2. Clinical characteristics from patients with heart failure and donors
The samples from patients undergoing heart transplants came from 7 males
(classification of heart failure: 5 ischemic and 2 non-ischemic) and 5 females
(classification of heart failure: all non-ischemic). The donor samples came from 3
males (cause of death: 2 head trauma and 1 unknown) and 2 females (cause of
death: stroke). The mean age of the patients with heart failure was 48 (range 19
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to 68), while that of donors was 41 (range 22 to 48). Patients’ characteristics are
summarized in table 2.1.

2.2.3. Multicellular preparations
Multicellular preparations (Fig. 2.1) were obtained by mechanically disrupting
~100 mg of tissue from the LV mid-myocardium or the RV. The preparations
were then permeabilized using 1% v/v Triton detergent (Fig. 2.1.1). A total of 79
multicellular preparations from 17 patients (5 non-failing and 12 failing hearts)
were analyzed. The average length of the preparations used in this study was
860 ± 248 µm, and the average cross-sectional area was 4.05 ± 2.08 x 10-8 m2.
Cross-sectional area was estimated assuming a circular profile.

2.2.4. Experimental set-up
Preparations were attached to a force transducer (resonant frequency, 600 Hz;
Model 403, Aurora Scientific, Aurora, Ontario, Canada) and a motor (step time
0.6 ms; model 312B, Aurora Scientific) (Fig. 2.1.2) and stretched to a sarcomere
length of 2.24 µm in a solution with a pCa (= -log10[Ca2+] of 9.0. All experimental
measurements were conducted at 15°C using SLControl software

96.

2.2.5. Solutions
Two set of solutions were used in this study. A relaxing solution to isolate and
permeabilize preparations, and experimental pCa (= -log10 [Ca2+]) solutions with
varying concentrations of Ca2+. The relaxing solution contained (in mmol L-1): 4
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ATP, 2 EGTA, 20 imidazole, 100 KCl and 7 MgCl2. The final pH of the relaxing
solution was adjusted to 7.0 with 4M KOH. To permeabilize the multicellular
preparations, double strength relax, water and two protease inhibitors
(phenylmethlsulfonide 500 µmol L-1 and leupeptin 40 µmol L-1) were added to
three beakers, the fourth beaker contained the aforementioned and triton. To
make a range of activating solutions (pCa solutions), two pCa (4.5 & 9.0)
solutions were initially made. Intermediate pCa solutions ranging from pCa 5.0 to
6.4 were made by combining different volumes of pCa 4.5 and 9.0. pCa 4.5
contained (in mmol L-1): 7 EGTA, 20 Imidazole, 52 KCL, 14.5 Creatine
phosphate, 4.9 ATP, 7 CaCl2, 5.23 mgCl2, sufficient amounts of KOH to get pH to
7.0. The composition of pCa 9.0 (in mmol L-1) was: 7 EGTA, 20 Imidazole, 68
KCL, 14.5 Creatine phosphate, 4.83 ATP, 5.41 MgCl2, and 13.7 µM CaCl2 plus
ample amount of KOH to reach pH 7.0. The ionic strength was held constant at a
180 mM in all solutions.

2.2.6. Force, rate of tension development, Ca2+ sensitivity measurements
Preparations were initially immersed in pCa 4.5 (saturating Ca2+ concentration).
Maximum isometric force (Fmax) was calculated as the force developed in this
solution at steady-state (Fig. 2.1.3). Once force reached steady state, the rate of
tension development, ktr, was measured by rapidly shortening the preparation by
20%, holding it at the short length for 20 ms, and then re-stretching the
preparation to its original length. The ktr was subsequently calculated by fitting
the portion of the force record immediately after the re-stretch with a single
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exponential function of the form F(t) = A + B(1-exp(-ktrt)). In this equation, F(t) is
the force at time t, and A and B are constants (Fig. 2.1.3). Calcium sensitivity
(pCa50) was determined by repeating the force measurements with different
solutions that had pCa values in the range 9.0 to 5.0. pCa50 values were
calculated by fitting the resulting data to a modified Hill equation of the form F =
Fpas + FCa ([Ca2+]n / ([Ca2+]n + [Ca2+ 50]n)), where Fpas is the force measured in pCa
9.0 solution; FCa is Ca2+ activated force; n is the Hill coefficient, and [Ca2+ 50]n is
the free Ca2+ concentration required to develop half the maximum Ca 2+
dependent force.

2.2.7. Shortening velocity and power measurements
To measure the shortening velocity and power, the multicellular preparations
were allowed to shorten for 80 ms against pre-set loads that ranged from 0 to
100% of the maximum tension measured in pCa 4.5 solution. The shortening
velocity in each trial was determined by fitting a regression line to a plot of fiber
length against time during the final 50 ms of the force clamp. The mean force
was also determined during this time. The resulting data were then fitted using a
hyperbolic equation of the form (F+a) (V+b) = (F0 +a) b, where F is the force
developed at a shortening velocity of V, F0 is the isometric force, and a and b are
constants with dimensions of force and velocity respectively. Power values were
calculated as the product of force and velocity. Fig. 2.1.4 illustrates a
representative force-velocity and power curves.
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2.2.8. Phosphorylation of myofilament proteins
The phosphorylation status of selected sarcomeric proteins was determined
using the protocol described in the supplemental materials of Haynes et al.

95.

Chemically permeabilized multicellular preparations utilized in the mechanical
measurements were initially homogenized in urea-thiourea sample buffer (in mol
L−1, 8 Urea, 2 Thiourea, 0.075 M DTT, and 0.05 Tris-HCl, with 3% SDS w/v, pH
6.8). 1 µg of protein was then loaded onto each lane of precast polyacrylamide
gels (12% 26 well Tris-HCl, Bio-Rad, Hercules, CA). Gels were first stained with
Pro-Q Diamond phosphoprotein stain (Invitrogen, Carlsbad, CA) and scanned
with a Typhoon 9410 scanner (GE Healthcare, Piscataway, NJ) to detect
phosphorylated proteins. The gels were then de-stained and subsequently
stained again with Sypro Ruby (Invitrogen, Carlsbad, CA) to assess total protein
content. The amounts of phosphorylated or total protein represented by each
band were determined by integrating the densitometry profile followed by
appropriate background correction. These calculations were performed using
GelBox software developed by our laboratory. Values from multiple gels were
normalized using data from a single homogenate that was run on each gel.
Relative phosphorylation was calculated as the ratio of the integrated densities
calculated for the Pro-Q Diamond and Sypro Ruby stains.

2.2.8.1. Western blot analysis of cTnI Ser-23/24 phosphorylation
TnI Ser23/24 specific phosphorylation was determined by Western blot similar to
that previously described Nixon et al. 97 and Salhi et al. 98. Briefly, whole cell
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homogenates from above were separated on a 12% (29:1) Laemmli gel and
transferred to Immobilon FL PVDF membrane (Millipore Sigma, Billerica, MA).
Following blocking with 1% BSA in TBS, TnI Ser-23 and Ser-24 phosphorylation
(pTnI S23/24) was detected by incubation with the rabbit anti-phosphorylated TnI
Ser-23/24 antibody (Cell Signaling Technology, Inc.). Following washes,
membranes were incubated with an anti-rabbit Cy5 labeled fluorescent
secondary antibody (Jackson ImmunoResearch Laboratories, Inc, West Grove,
PA), washed and visualized on a Typhoon 9410 imager (GE Healthcare,
Piscataway, NJ). Following TnI Ser-23/24 phosphorylation imaging, total TnI was
determined in the same membrane by re-incubation with the mouse anti-cardiac
TnI antibody (Fitzgerald; clone C5). Following washes, the membrane was
incubated with an anti-mouse Cy2 labeled fluorescent secondary antibody
(Jackson ImmunoResearch Laboratories, Inc, West Grove, PA), washed again
and visualized as above. Sequential development using different
primary/secondary combinations allows for quantification of phosphorylated and
total TnI species in the same membrane. Phosphorylation at Ser-23/24 and
expression of TnI was then quantified from the individual images with
ImageQuant TL v8.0 (GE Healthcare, Piscataway, NJ) and Ser-23/24
phosphorylation defined in arbitrary units as the TnI Ser-23/24 phosphorylation
signal divided by the total TnI signal.

2.2.9. Statistical analysis
The experimental data were analyzed in SAS 9.4 (SAS Institute, Cary, NC) using
linear mixed effects models incorporating two main effects (heart failure status
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and ventricular region) and their interaction. The linear mixed models were
chosen for the analysis for a few reasons. First, they accounted for the
unbalanced design (5 non-failing and 12 failing hearts). Second, the linear mixed
models took into consideration that certain regions (LV and RV) came from the
same person (repeated measures) and that from that LV or RV sample, there
were 2 to 3 preparations (hierarchical nesting). Thus, the linear mixed models
provided more statistical power than a standard two-way ANOVA tests when
multiple samples from each heart are analyzed. Post-hoc analysis was
performed using Tukey-Kramer corrections. P values less than 0.05 were
considered significant. Data are reported as mean ± SEM.
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Table 2.1. Patients’ characteristics
Age

Gender

Diagnosis

Cardiomyopathy/cause of death

22

Male

Non-failing

Head trauma

60

Female

Non-failing

Stroke

28

Male

Non-failing

Head trauma

47

Female

Non-failing

Stroke

48

Male

Non-failing

Unknown

68

Male

Failing

Ischemic

42

Male

Failing

Ischemic

53

Male

Failing

Ischemic

54

Male

Failing

Ischemic

64

Male

Failing

Ischemic

20

Male

Failing

Non-ischemic

35

Male

Failing

Non-ischemic

56

Female

Failing

Non-ischemic

66

Female

Failing

Non-ischemic

19

Female

Failing

Non-ischemic

60

Female

Failing

Non-ischemic

36

Female

Failing

Non-ischemic
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Figure 2.1. Multicellular preparation
4X magnification of permeabilized multicellular preparation. Each preparation
used in this and forthcoming studies contained between 10-20 single
cardiomyocytes.
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Figure 2.1.1. Permeabilization of preparations
Top left, human heart displaying right and left ventricles. Top excluding human
heart, homogenization, and permeabilization (skinning) process. Bottom left,
intact membrane. Bottom right, permeabilized membrane.
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Figure 2.1.2. Experimental setup
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Figure 2.1.3. Experimental record
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Figure 2.1.4. Representative force-velocity and force-power curves
A) Top panel, experimental records from one preparation demonstrating different
forces as a result of being held at different loads. Bottom panel, fiber length
records from each individual load the preparation was held at. B) Top panel,
shortening velocity curve. Bottom panel, power curve.
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2.3. Results
2.3.1. Heart failure has a greater effect on the Ca2 sensitivity of right
ventricular myocardium
Fig 2.2A shows that heart failure increased the sensitivity of the myofilaments to
Ca2+ (main effect for disease status, p=0.006). pCa50 increased from 5.60 ± 0.03
in the non-failing samples (mean ± sem of all non-failing samples from the LV
and RV) to 5.71 ± 0.02 in the samples isolated from patients who had heart
failure. The increase was greater for samples from the right ventricle (ΔpCa 50
~0.18, p<0.001) than for samples from the left ventricle (ΔpCa50 ~0.05, not
significant). These effects meant that there was a significant interaction (p<0.002)
between heart failure status and cardiac region for pCa50. A similar statistical
interaction (p=0.040) was measured for the Hill coefficient n (Fig 2.2B). The
effects of heart failure on the calcium sensitivity and cooperativity of the
myofilament thus depend on the ventricle that is being studied.

2.3.2. Heart failure reduces maximum force and maximum power output in
both ventricles
Fig 2.3 shows that preparations from the right and left ventricles generated
similar contractile force in maximally activating Ca2+ solution. On average, the
non-failing samples produced 25.3 ± 7.9 kN m-2, whereas samples from the LV
and RV of failing hearts produced 14.8 ± 5.2 kN m-2. Heart failure, therefore,
suppressed force by ~40% in both ventricles. Maximum power (where power was
measured as the product of force and velocity during loaded shortening) was
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also significantly reduced by heart failure (p<0.001 for both ventricles) (Fig 2.3B).
Vmax was not affected by ventricular region or heart failure status. On average,
Vmax was 1.09 ± 0.36 muscle lengths per second (l0 s-1) (Fig 2.4A). The rate of
tension development is also similar between the ventricles in non-failing and
failing preparations, as the average ktr was 0.88 ± 0.15 s-1 (Fig 2.4B).

2.3.3 Heart failure alters phosphorylation of myofilament proteins
The phosphorylation status of cTnI, cardiac myosin binding protein-C (cMyBP-C),
and myosin regulatory light chain (RLC) were assessed using Pro-Q Diamond
and Sypro Ruby (Fig. 2.5A). Figures 2.5B and 2.5C shows that the relative
phosphorylation of cTnI and RLC exhibited statistical interactions between
disease status and cardiac region. In non-failing hearts, the relative
phosphorylation of cTnI in the RV is ~24% higher than the LV. Conversely, in
failing preparations, the relative phosphorylation of cTnI in the LV is ~22% more
than the RV. The largest change in cTnI relative phosphorylation occurred in the
RV where heart failure produced ~49% reduction (p=0.029, Fig. 2.5B).

RLC relative phosphorylation exhibited a similar statistical interaction (Fig 2.5C).
Mean values were ~40% greater (p=0.041) in samples from non-failing RV than
in preparations from non-failing LV (p=0.041) whereas RV samples from failing
hearts had lower relative phosphorylation levels than in preparations from failing
LV.
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cMyBP-C relative phosphorylation levels did not demonstrate a significant
statistical interaction. However, heart failure significantly (p=0.017) reduced the
relative phosphorylation levels in both chambers (Fig. 2.5D).

Ser-23/24 is an important site for cardiac regulation on TnI. Measurements with
site-specific antibodies (Figs. 2.6A & B) shows a similar statistical interaction
(p=0.039) to the ProQ diamond cTnI (0.037) relative phosphorylation data (Figs.
2.5B).
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Figure 2.2. Heart failure impacts the calcium sensitivity and cooperativity of
myocardium from the left and right ventricles in different ways.
A) pCa50 and B) Hill coefficient. Symbols show data for 79 individual preparations
from n=5 non-failing and n=12 failing hearts.
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Figure 2.3. Heart failure reduces maximum force and maximum power in
both ventricles.
A) Force per cross-sectional area. B) Maximum power output. All data obtained
in maximally-activating solutions with pCa values of 4.5. Symbols show data for
79 individual preparations from n=5 non-failing and n=12 failing hearts.
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Figure 2.4. Shortening velocity and rate of force development are similar
between the ventricles.
A) Shortening velocity. B) The rate of tension development, ktr. All data obtained
in maximally-activating solutions with pCa values of 4.5. Symbols show data for
79 individual preparations from n=5 non-failing and n=12 failing hearts.
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Figure 2.5. Myofilament protein phosphorylation in the RV and LV of nonfailing and failing samples.
A) Images of representative gels stained with ProQ (left) and SYPRO Ruby
(right). Symbols show data from 8 failing and 4 non-failing hearts (non-failing
samples were run in duplicate). Individual bands were normalized to loading
control. B) Relative phosphorylation of cTnI, C) cMyBP-c, and D) RLC.
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Fig 2.6. Phosphorylation of TnI Ser 23/24 exhibits a statistical interaction
between heart failure status and cardiac region.
A) Representative western blot for TnI Ser-23/24 phosphorylation, and B) total
TnI. C) Quantification. Gel labels for panels A and B: Marker; molecular weight
marker, H TnI; purified recombinant human cardiac TnI, M TnI; purified
recombinant mouse cardiac TnI, M PKA TnI; PKA-treated purified recombinant
mouse cardiac TnI containing Ser-23/24 phosphorylation.
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2.4. Discussion
This study shows for the first time that multicellular preparations from the RV and
LV of human myocardium have similar mechanical properties when maximally
activated but different sensitivities to activating Ca2+. Intriguingly, in non-failing
hearts, preparations from the RV are less sensitive to Ca2+ than preparations
from the LV. In failing hearts, the opposite behavior occurs; RV samples are
more sensitive to Ca2+. Additional biochemical data suggest that these ventriclespecific effects are driven by changes in the relative phosphorylation of cTnI.

2.4.1. Mechanical properties of non-failing tissue
One of the long-standing questions in cardiac biology is whether interventricular
differences in myocardial contraction contribute to the higher systolic pressure
generated by the LV. To address this question, we measured Fmax, maximum
power output, and maximum shortening velocity, and rate of tension
development in non-failing human myocardium from the RV and LV. The data
show (Figs. 2.3 & 2.4) that none of these parameters exhibited significant interventricular differences.

To our knowledge, our study is the first to measure these mechanical properties
using permeabilized human samples. However, Belin et al. 7 and Perreault et al.
10

had already shown similar Fmax results using permeabilized myocardium from

rats. Other groups had compared the properties of living (electrically-excitable)
human tissue. For example, Harding et al. 13 showed that unloaded shortening
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velocity did not differ between cells from the LV and RV. Together these data
suggest that myocardium from the LV and RV has similar contractile properties.
Inter-ventricular differences in pressure are therefore most likely to reflect
chamber-specific fiber alignments and geometries.

2.4.2. Mechanical properties in failing tissue
One of our previous studies showed that end-stage heart failure reduces Fmax
and maximum power without altering shortening velocity in multicellular
preparations from the LV of human hearts

95.

The biochemical data from that

study suggested that the reduction in maximal force was most likely to result from
increased collagen deposition in the failing tissue. In this study, we aimed to test
if heart failure has a similar impact on the mechanical properties of both
ventricles. Our data (Figs. 2.3 & 2.4) show that this is indeed the case. Heart
failure reduced Fmax by ~40% and maximum power out by ~30% in samples from
both ventricles without changing shortening velocity or ktr. Heart failure thus
seems to produce similar contractile deficits in both chambers.

2.4.3. Calcium sensitivity
To our knowledge, this study is the first to demonstrate that human myocardium
from the RV and LV has different sensitivities to activating Ca2+. The pCa50 and
Hill coefficient data both displayed an interaction between disease status and
cardiac region, with the biggest change in pCa50 and cooperativity occurring
between the RV of non-failing and failing hearts (Figs 2.2A & B). In non-failing
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cardiac tissue, pCa50 and Hill coefficient values were higher in the LV.
Conversely, in failing preparations, the RV had higher pCa50 and Hill coefficient
values.

Our data from non-failing hearts are consistent with prior measurements in rats
performed by Belin and colleagues 7 and Perreault et al. 10. There are, however,
some subtle differences between the datasets for failing tissue. Belin et al. 7
found that heart failure reduced pCa50 in single cells isolated from the LV but had
no effect on RV cells. Perreault et al. 10 used multicellular preparations and
demonstrated that heart failure increased pCa50 in RV myocardium but had no
effect on LV tissue. It is not clear why the three studies produce slightly different
results, but inter-species effects, differences between single cells and multicellular preparations, and/or statistical variation could be contributing factors.

2.4.4. Phosphorylation of myofilament proteins
It is well known that increased phosphorylation of cTnI (most notably at Ser23/24) reduces myofilament Ca2+ sensitivity 85,86,89,92,99-103. Our data (Figs 2.5B
and 2.6C) suggest that this modification may be driving the changes we observe
in pCa50 (Fig 2.2A). All three datasets (pCa50, global cTnI phosphorylation
assessed with ProQ Diamond, and Ser-23/24 phosphorylation assessed by
western blot) exhibited statistical interactions between heart failure status and
cardiac ventricle, with lower pCa50 values (decreased Ca2+ sensitivity) being
associated with greater cTnI phosphorylation.
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RLC relative phosphorylation also exhibited a significant statistical interaction
(Fig 2.5C) with higher phosphorylation levels again being associated with
reduced Ca2+ sensitivity. This is a more complex relationship because increased
phosphorylation of RLC is known to enhance Ca2+ sensitivity 104,105. We,
therefore, think that RLC phosphorylation levels may change in human heart
failure to compensate for the posttranslational modifications to cTnI partially.

This interpretation is similar to that described by van der Velden and coworkers
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in their study of end-stage human heart failure. Like us, these authors
demonstrated parallel changes in the relative phosphorylation of RLC and cTnI.
They concluded that RLC might be dephosphorylated during human heart failure
to protect against enhanced Ca2+ sensitivity / diastolic dysfunction resulting from
dephosphorylation of cTnI. Our data are consistent with this general hypothesis,
but the molecular mechanisms need to be tested in additional future studies.

The data describing cMyBP-C phosphorylation are probably simpler to interpret.
cMyBP-C was dephosphorylated in failing samples, but there were no interventricular effects (Fig 2.5D). Reducing cMyBP-C phosphorylation increases
myofilament Ca2+ sensitivity 106-109 so this posttranslational modification may be
driving the global increase in Ca2+-sensitivity observed in the failing samples (Fig
2.2A).
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In summary, these biochemical data suggest that changes in cTnI
phosphorylation are driving inter-ventricular differences in calcium sensitivity
while dephosphorylation of cMyBP-C contributes to a global increase in pCa50
values during heart failure.

2.4.5. Source of intra-ventricular variation
We do not know why the LV and RV have different Ca 2+ sensitivities. They may,
for instance, be tuned to different mechanical loads. Another possibility is that
they are responding differently to β-adrenergic stimulation. Molina et al. 110
showed that the RV was more sensitive to β-adrenergic stimulation than the LV
in healthy dogs and that the enhanced sympathetic response preferentially
increased PKA activity in right ventricular tissue.

PKA increases phosphorylation of cTnI 111 so differential responses to βadrenergic stimulation could contribute to the inter-ventricular effects that we
measured for cTnI modifications (Fig 2.5B, 2.6C). However, region-specific
changes in PKA activity would also be expected to produce enhanced cMyBP-C
phosphorylation in non-failing myocardium from the right ventricle, which we did
not observe. Neither is it clear whether human ventricles respond to β-adrenergic
stimulation in the same way as canine tissue. More experiments in this area are
required.
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2.5. Conclusion
This study presents three important results. First, human heart failure increases
the Ca2+ sensitivity of right ventricular myocardium more than the calcium
sensitivity of left ventricular myocardium. Second, this contractile effect is likely to
involve inter-ventricular differences in posttranslational modifications to
sarcomeric proteins including TnI. Third, heart failure depresses maximum force
and maximum power by similar amounts in tissue from both ventricles.
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Chapter 3
Omecamtiv mecarbil increases Ca2+ sensitivity and decreases the rate of
force development in failing human hearts

The content reported in this chapter has been published in “Swenson, A.M.,
Tang, W., Blair, C.A., et al. Omecamtiv Mecarbil Enhances the Duty Ratio of
Human beta-Cardiac Myosin Resulting in Increased Calcium Sensitivity and
Slowed Force Development in Cardiac Muscle. The Journal of biological
chemistry 292, 3768-3778, doi:10.1074/jbc.M116.748780 (2017). PMID
28082673 112.

In this dissertation, only the information about the mechanical analysis from this
study will be discussed.

3.1. Introduction
Heart failure is a clinical syndrome caused by cardiac dysfunction

113.

In the

United States, it affects ~6 million Americans and is the main reason for hospital
admissions in the elderly 114-116. The most common manifestation of the
syndrome is systolic heart failure which is marked by decreased contractility

64.

Many factors can change the function of the heart that can lead to heart failure,
including cell death, impaired calcium handling, neurohumoral disturbances, and
changes in cardiac structure (hypertrophy or dilation)

57

117-119.

However, in patients

suffering from systolic heart failure, sarcomeric dysfunction plays a central role
75,120.

Patients who suffer from systolic heart failure are often prescribed positive
inotropes to increase contractility and cardiac output. Inotropic drugs are agents
that enhance myocardial contractile force 121 (Fig. 3.1 50,122). Some of the current
inotropes used in clinical practice include adrenergic receptor agonist such as
Norepinephrine, and Dobutamine, as well as the phosphodiesterase inhibitor
Milrinone 121. At the basic level, an increase in contractile force is accomplished
by altering actin-myosin interactions. Existing Inotropic agents alter the actinmyosin interaction by indirectly activating the secondary messenger signaling
pathways that increase intracellular Ca2+ concentrations 121. The result of these
mechanisms is an increase in the number of myosin heads attached to actin
filaments because of increased Ca2+ binding to troponin C, which increases
contractile force. While these inotropes increase contractility, unfortunately, they
also increase heart rate, myocardial oxygen consumption, and can produce
arrhythmias, all of which can contribute to higher mortality rates

122-124.

To overcome the deleterious effects of current inotropes, drugs that directly
target the sarcomeres of cardiac tissue are being developed. One class of such
compounds that directly influence the cross-bridge cycle are called cardiac
myosin activators 125 (Fig. 3.1 50,122). The first of such drugs that have shown
signs of overcoming the harmful effects of current inotropes is omecamtiv
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mecarbil (OM) 124. In studies in dogs 63 and rats 64, OM improved cardiovascular
function without increasing myocardial oxygen consumption or altering Ca 2+
transients. Thus, OM is the first cardiac myosin activator that has made it into
clinical trials 126-128.

For sarcomeres to generate force, actin and myosin must interact

129.

During the

actin-myosin cross-bridge cycle, actin and myosin undergo weak and strong
binding (Fig.3.2 62). The cycle is initiated by the binding of ATP to myosin which
allows myosin to dissociate from actin rapidly. The rapid hydrolysis of ATP to
ADP and Pi by the ATPase of the cross-bridges (S1 in Fig 3.1) creates a weak or
electrostatic contact between actin and myosin. Upon binding, the newly formed
actin-myosin-ADP-Pi complex undergoes an activation step which concomitantly
involves the release of Pi and the transition of actin and myosin from a weaklybound to a strongly-bound state (Fig. 3.2 62) 130. It is also during the release of Pi
were the cross-bridges undergo a conformational change producing a ~10 nm
power-stroke which contracts the muscle. The transition from the weak to
strongly bound state between actin and myosin is a critical step, as it dictates the
amount of force the muscle will be able to produce

131,132.

OM accelerates this

transition, as the drug increases the rate of phosphate release (Fig. 3.2
forcing actin and myosin into the strong force producing state faster

62)

64,133,134.

Thus, OM enhances the number of myosin heads in the strongly-bound force
generating state at any given time during the cross-bridge cycle, which increases
the amounts of cross-bridges pulling on actin.
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The impact of OM on cardiac function in a dose-dependent manner in humans
has not been studied. This study aims to test the hypothesis that OM alters the
mechanical properties of permeabilized human cardiac tissue in a dosedependent manner.
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Figure 3.1. Selected inotropes mode of action
Figure was made by combining and modifying figures from Hwang & Sykes,
2015 50 and Tarone et al., 2014 122
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Figure 3.2. Actin-Myosin cross-bridge cycle illustrating the segment of the
cycle (between 3a and 3b) omecamtiv mecarbil is proposed to influence
Figure modified from James Spudich, 2014
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3.2. Methods
The human cardiac samples used for this study were procured as described in
the methods section of chapter 2, section 2.2.1.

3.2.1. Clinical characteristics of patients with heart failure
The samples from patients undergoing heart transplants came from 3 males
(classification of heart failure: 2 ischemic and 1 non-ischemic) and 5 females
(classification of heart failure: 1 ischemic and 4 non-ischemic). The mean age of
the patients was 50 (range 31 to 68). Patients’ characteristics are summarized in
table 3.1.

3.2.2. Multicellular preparations
Permeabilization of human tissue was performed as described in section 2.2.3. A
total of 46 multicellular preparations from 8 patients with heart failure were
analyzed. The average length of the preparations used in this study was 1055 ±
229 µm, and the average cross-sectional area was 5.87 ± 2.42 x 10-8 m2. Crosssectional area was estimated assuming a circular profile.

3.2.3. Incubation of multicellular preparations
Solutions with pCa values ranging from 9.0 to 4.5 (made as described in the
methods section of chapter 2, section 2.2.5) and OM concentrations of 0.1, 1.0,
or 10 µM were made by adding suitable amounts of OM dissolved in DMSO. The
final percentage of DMSO in every experimental solution was 0.67%.
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Preparations were immersed in a pCa 9.0 solution containing 0 (control), 0.1, 1.0,
or 10.0 µM for at least 3 min between trials. The ionic strength was held constant
at 180 mM in all solutions.

3.2.4. Mechanical measurements
Pilot test showed that OM is hard to wash out of the multicellular preparations.
Each preparation was therefore exposed to only one concentration of OM (0, 0.1,
1.0, or 10 µM). All experimental measurements were conducted at 15°C using
the experimental set-up describes in section 2.2.4 and SLControl software

96.

For

this study only maximum force, the rate of tension development, and Ca2+
sensitivity as described in section 2.2.6 were measured. Shortening velocity and
maximum power measurements were not performed in this study. The higher
concentrations of OM (1.0 and 10 µM) altered the natural properties of
multicellular preparations so these measurements could not be done with
accuracy.

3.2.5. Statistical analysis
A linear mixed model approach that took into account drug concentration and
multiple preparations from the same patient was used to analyze 46 multicellular
preparations from 8 patients.
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Table 3.1. Patients’ characteristics
Age

Gender

Diagnosis

Cardiomyopathy

56
36

Female
Female

Failing
Failing

Non-ischemic
Noon-ischemic

59

Female

Failing

Ischemic

31

Female

Failing

Non-ischemic

66
37
68

Female
Male
Male

Failing
Failing
Failing

Non-ischemic
Ischemic
Ischemic

47

Male

Failing

Non-ischemic
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3.3. Results
3.3.1. OM increases Ca2+ sensitivity and decreases the rate of force
development
The effects of OM on the mechanical properties of human myocardium were
measured using chemically permeabilized multicellular preparations. The
maximum isometric force was not significantly altered by OM (Fig. 3.3). In
contrast, 1 and 10 µM OM significantly (p<0.001) increased pCa50 (Fig. 3.4). In
comparison to vehicle, 1 µM OM increased pCa50 from 5.55 ± 0.06 to 5.83 ± 0.08
(p<0.001), while 10 µM OM increased pCa50 from 5.55 ± 0.06 to 6.05 ± 0.18
((p<0.001). These concentrations of OM also slowed ktr, the rate of force
development (ktr in OM-free medium: 1.04 ± 0.26 s-1; in 1 µM OM: 0.33 ± 0.11 s-1
(p<0.001 vs OM free medium); in 10 µM OM 0.17 ± 0.16 s-1 (p<0.001 vs OM free
medium)) (Fig. 3.5).
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Figure 3.3. OM does not alter maximum force
All data obtained in maximally-activating solutions with pCa values of 4.5.
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Figure 3.4. OM increases Ca2+ sensitivity in a dose-dependent manner
All data obtained in maximally-activating solutions with pCa values of 4.5.
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Figure 3.5. OM decreases the rate of force development
All data obtained in maximally-activating solutions with pCa values of 4.5.
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3.4. Discussion
The impact of omecamtiv mecarbil on the mechanical properties of permeabilized
cardiac tissue has been studied in rats 135 and humans 136. In rats, OM increased
calcium sensitivity, slowed the rate of force development, and enhanced force in
sub-maximal calcium concentrations 135. Mamidi et al. 136 performed similar
measurements in humans, using 1 µM OM in sub-maximal calcium
concentrations. They reported that OM increased isometric force and calcium
sensitivity. Our study adds to the findings of Mamidi and coworkers 136 by further
examining the impact of OM on human myocardium in a dose-dependent
manner. We find an increase in calcium sensitivity in a dose-dependent manner
with little change in steady-state force at maximum calcium concentrations. Also,
we observe a decrease in the rate of force development.

The fraction of cross-bridges bound to actin in the strongly bound state at any
moment during the actin-myosin ATPase cycle is referred to as the “duty ratio”
137.

By increasing the duty ratio, you increase cooperative activation of the thin

filament making it more sensitive to calcium

138,139.

Additionally, an increase in the

duty ratio could reduce the rate of force development by slowing the detachment
of strongly-bound myosin heads from actin. To determine if OM increased the
duty ratio, in vitro motility assays were performed (not included in the
dissertation, but was done by collaborator for manuscript). The results of the in
vitro motility assays showed that OM increased the duty ratio, and trapped a
population of myosin heads in a weakly-bound state with actin, slowing
phosphate release 112. Thus, we propose that OM increases calcium sensitivity
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by increasing the duty ratio. Additionally, the data suggest that the reduction in
the rate of force development could be the result of the increase in weakly bound
non-force generating cross-bridges, or because of the increase in the duty ratio,
which would slow the detachment of cross-bridges.

Shortening velocity measurements were attempted in the mechanical
measurements. However, at OM concentrations of 1 and 10 µM, shortening
velocity measurements could not be accurately obtained with the multicellular
preparations. The drug drastically reduced force development; thus, when
performing the load clamps (changing the length of the preparation), an accurate
measurement of the force generated by multicellular preparation could not be
obtained. Therefore, shortening velocity measurements were not recorded.
However, sliding velocity measurements were performed by our collaborators.
Using in vitro motility assays, they were able to measure the sliding velocity of
actin with the same human cardiac samples used for the multicellular preparation
experiments (all of these data are published in the manuscript by Swenson et al.
112).

Similar to the rate of force development, the results of the motility assay

showed that OM significantly reduced sliding velocity 112. These findings are
consistent with earlier studies in pigs 140,141 and humans 142. From the results of
the motility assays, it was proposed that in the presence of OM a population of
myosin heads is consistently cycling from a detached to a weakly-bound state
with actin, which slows phosphate release creating a viscous drag that reduces
the actin sliding velocity.
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3.5. Summary
The discovery of omecamtiv mecarbil as an inotrope that can alter contractile
properties without changing calcium homeostasis and myocardial oxygen
consumption is promising for patients suffering from systolic heart failure. The
drug has made it into clinical trials. A phase I trial demonstrated an improvement
in systolic ejection time and stroke volume
showed increased systolic ejection time

126.

143.

Similarly, a phase II trial also

Both studies reported that the effects

are dose-dependent. Overall, it appears that dosing could be critical to receive
the maximum benefits of the drug. The findings of this and previous studies also
would suggest that an appropriate dose of OM is essential, as too much of the
drug can slow force development and increase calcium sensitivity, which may
impact the rate of relaxation.
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Chapter 4
Para-Nitroblebbistatin reduces maximum force and calcium sensitivity in
human myocardium

The effects of para-Nitroblebbistatin on the mechanical function of human
myocardium are published in, Tang, W., Blair, C.A., et al. Modulating BetaCardiac Myosin Function at the Molecular and Tissue Levels. Frontiers in
Physiology 7, doi:10.3389/fphys.2016.00659 (2017). PMID: 28119616

144.

In this dissertation, only the information about the mechanical analysis from this
manuscript will be discussed.

4.1. Introduction
Hypertrophic cardiomyopathy (HCM) is the most common occurring inherited
cardiac disease 145. Clinically, HCM is characterized by hypertrophy of the
ventricles and interventricular septum in the absence of predisposing conditions
such as hypertension or aortic stenosis 146. Consequently, the interior diameters
of the chambers decrease, ventricular compliance is reduced, and diastolic
function is impaired 147. Pathologically, HCM results in disarrayed
cardiomyocytes and increased fibrosis 148. The disease is prevalent, as 1 in 500
individuals are affected by HCM which may result in heart failure or sudden death
149.

HCM is a disease of the sarcomere, as up to 60 to 70% of HCM cases are
attributed to mutations in sarcomeric proteins 150-152. Defects in genes encoding
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myosin heavy chain 153, myosin essential 154 and regulatory light chains 155,
myosin-binding protein C 156, actin 157, tropomyosin 158, troponins I 159, C 160 and
T 161 have all been associated with HCM. The most common being mutations in
the human β-cardiac myosin heavy chain, which accounts for ~40% of HCM
cases 162,163. Within the entire human β-cardiac myosin (heavy and light chains),
there have been over 300 pathogenic mutations described, most of which are in
the motor (subfragment 1 (S1)/cross-bridges) domain 164-166.

Human β-cardiac myosin is the motor that drives contraction. Studies have
shown that mutations in this protein can make the heart hypercontractile

167,168.

At the mechanical level, a hypercontractile heart generates more power (product
of force and velocity). Thus, patients suffering from HCM as a result of myosin
mutations often exhibit hyperdynamic (substantially high ejection fraction)
ventricular function 169. Currently, there is no pharmacological therapy for HCM.
However, small molecules that can reduce the amount of force (i.e., reduce
power) by lowering the duty ratio (fraction of cross-bridges bound to actin in the
strongly bound state at any moment during the ATPase cycle) has the potential
to help patients suffering from HCM with hyperdynamic ventricular function.

Blebbistatin is a small molecule used as an experimental tool to inhibit myosin
function 170,171. The molecule was first identified as a non-muscle myosin II
specific inhibitor but has seen been shown to inhibit myosin in striated muscle as
well 65,172. Blebbistatin inhibits the force generating capacity of myosin by
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specifically binding to the myosin-ADP-Pi complex which slows the release of
inorganic phosphate, trapping cross-bridges in the weakly bound state with actin
(Fig. 4.1 62) 170-172. Additionally, studies have shown that Blebbistatin can reduce
the amount of force cardiac tissue produce by stabilizing the binding of myosin
heads to the thick filament 173-175, thus removing the ability of cross-bridges to
interact with actin. The folding of myosin heads where they cannot interact with
the thin filament is referred to as the super-relaxed state 176. The mechanism by
which Blebbistatin anchors myosin heads to thick filaments is unknown

175.

In

rodents, the effects of Blebbistatin were shown to be dose-dependent, as Dou et
al. 177 demonstrated that mice given different doses of Blebbistatin decreased
twitch force and shortening velocity in a dose-dependent manner.

In its general form, the use of Blebbistatin as an experimental tool is hindered, as
blue-light exposure reverses it inhibitory effects

178.

Additionally, the molecule is

cytotoxic, phototoxic, and has poor solubility 179. To address these issues, more
soluble, non-cytotoxic, non-phototoxic, non-fluorescent derivatives called paraNitroBlebbistatin (pN-Bleb) and para-amino-blebbistatin has been synthesized
180,181.

These derivatives exhibit the same myosin inhibitory effects.

This study aimed to test the hypothesis that pN-Bleb will alter the mechanical
properties of human cardiac tissue from patients with heart failure. The results of
our study show that pN-Bleb reduces maximum force, power, and calcium
sensitivity without altering shortening velocity or the rate of tension development.
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These data provide evidence that drugs designed to reduce myosin duty ratio by
inhibiting strong attachment to actin can potentially treat patients with HCM.

4.2. Methods
The human cardiac samples used for this study were procured as described in
the methods section of chapter 2, section 2.2.1.

4.2.1. Clinical characteristics of patients with heart failure
The samples from patients undergoing heart transplantation came from 2 males
(classification of heart failure: 1 ischemic and 1 non-ischemic) and 2 females
(classification of heart failure: 2 non-ischemic). The mean age of the patients was
45 (range 31 to 68). Patients’ characteristics are summarized in Table 4.1.

4.2.2. Multicellular preparations
Permeabilization of human tissue was performed as described in section 2.2.3. A
total of 46 multicellular preparations from 8 patients with heart failure were
analyzed. The average length of the preparations used in this study was 1047 ±
232 µm, and the average cross-sectional area was 5.07 ± 2.47 x 10-8 m2. Crosssectional area was estimated assuming a circular profile.

4.2.3. Solutions
The ionic composition of the pCa solutions used in this study was adjusted for
use at 22° C. The ionic strength was held constant at 180 mM in all solutions.
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The relaxing solution used to isolate and permeabilize multicellular preparations
did not change from what was described in chapter 2, section 2.2.5. To make the
pCa solutions, we initially made pCa 4.5 & 9.0. Those two pCa solutions were
then mixed to make intermediate concentrations ranging from pCa 5.0 to pCa
6.4. The composition of pCa 4.5 (mmol L-1): 7 EGTA, 20 Imidazole, 51 KCL, 14.5
Creatine, 4.8 ATP, 7 CaCl2, 5.22 mgCl2, sufficient amounts of KOH to get pH to
7.0. The composition of pCa 9.0 (in mmol L-1): 7 EGTA, 20 Imidazole, 68 KCL,
14.5 Creatine phosphate, 4.74 ATP, 5.48 MgCl2, and 15.3 µM CaCl2 plus ample
amount of KOH to reach pH 7.0.

4.2.4. Incubation of samples with pN-Bleb
pN-Bleb combined with Dimethyl sulfoxide (DMSO) was added to pCa values
ranging from 9.0 to 4.5 to create solutions with a final concentration of 0 (DMSO
only), 1,10, or 50 μM pN-Bleb. The final percentage of DMSO in every
experimental solution was 1.33%. Each preparation was initially tested in control
solutions (0 pN-Bleb) with pCa values ranging from 9.0 to 4.5. The preparation
was then immersed for 5 min in a pCa 9.0 solution containing 1, 10, or 50 μM pNBleb. Mechanical experiments described in sections 2.2.6 and 2.2.7 were then
performed to assess maximum force, calcium sensitivity, the rate of force
development, shortening velocity and maximum power. These samples were
only tested in pCa 4.5 solutions with 0 pN-Bleb(control) and then a chosen
experimental pN-Bleb concentration. These experimental designs ensured that
each preparation could act as its own control and minimized the progressive
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decline in contractile force (experimental run-down) that occurs when
permeabilized preparations are subjected to repeated activations.

4.2.5. Statistical analysis
The same linear mixed model used in section 3.2.5 was used to analyze the 24
multicellular preparations from the 4 patients used in this study.
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Figure 4.1. pN-Blebb mode of action
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Table 4.1. Patients’ characteristics
Age

Gender

Diagnosis

Cardiomyopathy

36

Female

Failing

Non-ischemic

31

Female

Failing

Non-ischemic

68
47

Male
Male

Failing
Failing

Ischemic
Non-ischemic
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4.3. Results
4.3.1. pN-Bleb reduces maximum force and power
To assess the impact of pN-Bleb on the mechanical function of permeabilized
human hearts, I measured force, tension recovery, Ca2+ sensitivity, shortening
velocity and power in maximum Ca2+ solution containing either control (DMSO
only), 1, 10, or 50 µM pN-Bleb. Figure 4.2 shows the maximum force and
maximum power of 1, 10 and 50 µM pN-Bleb normalized to control. Maximum
force (Fig. 4.2A) was significantly different (p=0.020) between the 1 µM and 50
µm pN-Bleb. The maximum power generated by the preparations were
significantly reduced at 50 µM (p<0.001) and 10 µM (p=0.024) pN-Bleb (Fig.
4.2B). Neither maximum shortening velocity (Fig. 4.3A) or rate of tension
recovery (ktr) (Fig. 4.3B) changed between the varying concentrations of pNBleb.

Figure 4.4A shows tension-pCa curves of 1, 10 and 50 µM pN-Bleb normalized to
control. The curves indicate that in addition to reducing relative force, pN-Bleb
also reduced Ca2+ sensitivity (pCa50 values; Fig. 4.4B) and the Hill coefficient
(Fig. 4.4C). The effects of pN-Bleb on pCa50 and the Hill coefficient were only
significant at the 50 µM concentration.
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Figure 4.2. pN-Bleb reduced maximum force and maximum power.
The left- hand panels show data measured in pCa 4.5 solution plus 1.33%
DMSO. Right- hand panels show data measured in pCa 4.5 solution plus 1.33%
DMSO and either 1, 10, or 50 µM pN-Bleb. The different concentrations of pNBleb were normalized to the control (DMSO only). A) Maximum force, and B)
maximum power.
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Figure 4.3. pN-Bleb does not alter shortening velocity or the rate of tension
recovery.
The left-hand panels show data measured in pCa 4.5 solution plus 1.33%
DMSO. Right-hand panels show data measured in pCa 4.5 solution plus 1.33%
DMSO and either 1, 10, or 50 µM pN-Bleb. The different concentrations of pNBleb were normalized to the control (DMSO only). A) Maximum shortening
velocity, and B) rate of tension redevelopment.
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Figure 4.4. Impact of pN-Bleb on Ca2+ sensitivity and isometric force.
A) Representative tension-pCa curves for multicellular preparations activated in
solutions with pCa values ranging from 9.0 to 4.5. The control (gray) data points
show force values measured in the presence of 1.33% DMSO. The red, green,
and blue data points show force measured in 1.33% DMSO plus 1, 10, or 50 µM
pN-Bleb. All force values were normalized to the control. B) pCa50 and C) Hill
coefficient results.
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4.4. Discussion
HCM is an inherited disease that can lead to a hypercontractile heart. Currently,
there is no effective treatment for the disease. However, small molecules may
serve as therapy to treat the disorder, as these compounds can regulate human
beta myosin, the primary protein driving the hypercontractile phenotype seen in
HCM patients. Utilizing a modified version of the myosin inhibitor blebbistatin, the
findings of this study suggest that small molecules designed to target human
hearts with myosin inhibitory capacity similar to that of blebbistatin may serve as
therapy for patients suffering from HCM. The results of the current research show
that pN-Bleb reduces maximum force, maximum power, and alter Ca2+ sensitivity
without changing the rate of cell shortening or tension recovery in human
myocardium.

While the interpretation of the force and power data is unambiguous, caution
should be taken when interpreting the pCa50 and Hill coefficient data. As shown
in figure 4.4, the pCa50 (Fig. 4.4B) and Hill coefficient (Fig. 4.4C) values
significantly decreased in the 50 µM pN-Bleb concentrations but did not
demonstrate any marked effects in the 1 or 10 µM concentrations. A possible
explanation for the reduction in pCa50 and Hill coefficients at 50 µM pN-Bleb
concentrations could be the absence of the flat plateau in the tension-pCa curve
at 50 µM. The absence of the flat plateau would suggest that isometric force did
not completely saturate in a pCa 4.5 solution in the presence of 50 µM pN-Bleb.
These data could indicate that a high concentration of pN-Bleb desensitizes the
thin filaments by reducing the myosin duty ratio which would lower pCa 50 and Hill
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coefficient values. Additionally, the low Hill coefficients and pCa50 values
measured in the presence of 50 µM pN-Bleb may also be explained by a
progressive reduction in force development during the experiments. In rodent
hearts, Dou et al. 177 showed that the effects of blebbistatin on force development
are time-sensitive, as it took ~30 min for the force to stabilize in the presence of
the drug. It is possible that similar time-dependent effects in human myocardium
might produce tension-pCa data similar to those shown in Figure 4.4A.

In the multicellular preparations, shortening velocity did not significantly vary
between the pN-Bleb concentrations. However, it is worth noting that sliding
velocity of S1 sub-fragment of myosin heads decreased in the in-vitro motility
assays (data not shown here, published in Tang, Blair...et al 144) exposed to the
same concentrations of pN-Bleb as in the human mechanics study. In the motility
assay, pN-Bleb reduced sliding velocity in a concentration-dependent manner.
These data suggest that differences observed in sliding velocity at the molecular
level do not translate to the tissue level. However, these differences between the
molecular and tissue level may reflect the structural organization of the myosin
heads at the tissue level. Within the tissue, there are many myosin heads near
actin filaments, whereas in the motility assay not as many heads are interacting
with actin filaments. Thus, the lowered sliding velocity observed at the molecular
level could reflect the sensitivity of smaller amounts of heads to pN-Bleb
inhibition that is not present in the larger organized tissue. To support this
hypothesis, Fusi et al. 182 showed that only 1-4 myosin heads per thick filament
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are required to sustain maximum shortening velocity in muscle fibers. Thus, even
though some heads may be experiencing pN-Bleb effects in the tissue, there are
enough heads that are not undergoing inhibition to maintain shortening velocity.

The use of small molecules that target the contractile apparatus to treat cardiac
dysfunction has garnered a lot of attention, as some of these molecules have
shown promise and have made it into clinical trials. For example, the
aforementioned omecamtiv mecarbil (studies in chapter 3), and more recently,
MYK-461. Similar to pN-Bleb, MYK-461 reduces the rate of phosphate release in
the actin-myosin ATPase cycle. A recent study suggests that MYK-461 can
diminish the hypercontractile nature of HCM hearts by reducing the myosin duty
rate, thus decreasing the force and power 183. These findings were demonstrated
in rodent hearts. The results reported in this dissertation and the manuscript
published by Tang, Blair, et al., 144 would suggest that MYK-461 should have
similar effects in humans, as the mode of action of both molecules is similar. The
findings of this study and the use of MYK-461 in rodents to treat HCM are
exciting, as they provide evidence that small molecules can potentially be used to
treat patients with who suffer from HCM. However, more research is needed to
see how effective compounds like MYK-461 are in patients with a variety of HCM
mutations.
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Chapter 5
Engineered troponins modulate the Ca2+ sensitivity of the
failing human myocardium
5.1. Introduction
The troponin complex is a primary regulator of cardiac muscle contraction and
relaxation. It consists of troponin C (TnC) the Ca2+ binding subunit, troponin I
(TnI) the inhibitory subunit, and troponin T (TnT) the tropomyosin binding subunit.
For a muscle to contract, free Ca2+ ions must bind TnC, which releases the
inhibitory effects of TnI leading to a conformational shift in TnT, a cascade that
ultimately enables the interaction of actin and myosin. Contrarily, the removal of
Ca2+ ions from TnC must occur for actin and myosin to dissociate and relax the
muscle. Being the Ca2+ sensor, TnC plays an integral role in tuning the response
of the myofilament to Ca2+. However, the response of TnC to Ca2+ can be
potentiated or reduced by other myofilament proteins (TnI, TnT, tropomyosin,
and myosin) and by posttranslational modifications to many of these proteins 184186.

Myofilament calcium sensitivity is a concept researcher use to describe the
relationship between the concentration of free Ca2+ ions available to bind TnC
and the amount of force the muscle generates 187. While this reductionist
approach reduces a complex system to two variables: free Ca2+ ions and force of
contraction, it has provided significant insights into the mechanisms that govern
cardiac contractility. Typically, hearts with increased Ca2+ sensitivity are
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associated with increased contractility, whereas myofilaments that are less
sensitive to Ca2+ have reduced contractility 187.

A common observation in samples from patients with hypertrophic and dilated
cardiomyopathy, as well as systolic and diastolic heart failure, is aberrant
myofilament Ca2+ sensitivity 188-192. Although it is unclear the exact mechanism by
which Ca2+ sensitivity contributes to these etiologies, it is clear from studies in
rodents that correcting cardiac Ca2+ sensitivity through genetic manipulation of
myofilament proteins can restore normal myofilament Ca2+ sensitivities 193.
Specifically, Liu et al. 193 using permeabilized tissue showed that TnC engineered
to either increase or decrease Ca2+ sensitivity in rodent hearts with restrictive
(increased Ca2+ sensitivity) or dilated (decreased Ca2+ sensitivity)
cardiomyopathic mutations can restore normal Ca2+ sensitivity. Additionally,
Shettigar and coworkers 194 recently demonstrated that rationally engineered
troponins could be delivered in-vivo to correct and enhance cardiac function in a
rodent model.

Rodent models have shown that there are many ways to modulate the Ca 2+
sensitivities of cardiac muscle. However, it is unclear how engineered proteins
can alter Ca2+ sensitivities in human myocardium. In this study, engineered TnCs
and TnIs (Fig 5.1) were exchanged into the permeabilized human myocardium to
either increase or decrease myofilament Ca2+ sensitivity. The results show that
compared to the wild-type troponins, our Ca2+ sensitizing L48Q TnC and S150D
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TnI troponins exchanges both increased pCa50. Conversely, the Ca2+
desensitizing D73N TnC and Y26E TnI troponins exchanges both decreased
Ca2+ sensitivity. In the presence of saturating Ca2+, the maximal force per crosssectional area, shortening velocity, the rate of tension redevelopment (ktr) and
power were all similar for the exchanged troponins suggesting the modified
troponins have a negligible direct impact on myosin function. This study
demonstrates that the myofilament responsiveness of the failing human heart to
Ca2+ can be modulated by engineering either TnC or TnI. These findings open
the door to potential new troponin targeted therapies for heart disease.
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Figure 5.1. Ribbon representation of troponin complex with TnC and TnI
mutations used in this study
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5.2. Methods
The human cardiac samples used for this study were procured as described in
the methods section of chapter 2, section 2.2.1.

5.2.1. Clinical characteristics of patients with heart failure
The samples from patients undergoing heart transplantation came from 3
females (classification of heart failure: 3 non-ischemic). The mean age of the
patients was 48 (range 31 to 65). Patients’ characteristics are summarized in
Table 5.1.

5.2.2. Multicellular preparations
Permeabilization of human tissue was performed as described in section 2.2.3. A
total of 18 multicellular preparations from 3 patients with heart failure were
analyzed. The average length of the preparations used in this study was 973 ±
138 µm, and the average cross-sectional area was 4.97 ± 2.35 x 10-8 m2. Crosssectional area was estimated assuming a circular profile.

5.2.3. Solutions
The ionic composition of the pCa solutions used in this study was adjusted for
use at 22° C. The ionic strength was held constant at 180 mM in all solutions.
The relaxing solution used to isolate and permeabilize multicellular preparations
did not change from what was described in chapter 2, section 2.2.5. To make the
pCa solutions, we initially made pCa 4.5 & 9.0. Those two pCa solutions were
then mixed to make intermediate concentrations ranging from pCa 5.0 to pCa
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6.4. The composition of pCa 4.5 (mmol L-1): 7 EGTA, 20 Imidazole, 51 KCL, 14.5
Creatine, 4.8 ATP, 7 CaCl2, 5.22 mgCl2, sufficient amounts of KOH to get pH to
7.0. The composition of pCa 9.0 (in mmol L-1): 7 EGTA, 20 Imidazole, 68 KCL,
14.5 Creatine phosphate, 4.74 ATP, 5.48 MgCl2, and 15.3 µM CaCl2 plus ample
amount of KOH to reach pH 7.0.

5.2.4. Incubation of samples with engineered troponins
The engineered troponins used in this study were sent to us from our
collaborators at the Ohio State University. Including wild-type, there were five
troponin complexes used in this study. The constructs of each troponin complex
have in the abbreviation “Hc” for human cardiac, “Tn” for troponin, and either
“WT” for wild-type,” or a letter with a number and another letter representing the
amino acid substitution for either TnC or TnI. The constructs are as followed:
•

HcTn WT (Human cardiac troponin containing TnT WT with a Myc Tag / TnC
WT / TnI WT) at 10uM

•

HcTn L48Q (Human cardiac troponin containing TnT WT with a Myc Tag /
TnC with L48Q mutation +IAANS / TnI WT) at 11uM

•

HcTn D73N (Human cardiac troponin containing TnT WT with a Myc Tag /
TnC with L48Q mutation / TnI WT) at 11uM

•

HcTn S150D (Human cardiac troponin containing TnT WT with a Myc Tag /
TnC WT / TnI Ser-150 with Asp pseudophos) at 11uM

•

HcTn Y26E (Human cardiac troponin containing TnT WT with a Myc Tag /
TnC WT / TnI Tyr-26 with Glu pseudophos) at 11uM

93

All troponin complexes contain TnC with the fluorescent labeled T53C mutation
that does not alter function and was in Exchange buffer (0.2M KCl, 5mM MgCl2,
5mM EGTA, 1mM DTT, 20mM MOPS, pH 6.5).

To exchange the engineered troponin complexes with the native troponin
complexes, two to three permeabilized preparations were placed in one of the
wells in a 96 well microtiter plate. The preps were then incubated for 24-hours
with 100 µL of one of the five troponin constructs at 4°C. The next day; the
preparations were then removed from the plate to carry out the mechanical
experiments described in sections 2.2.6 and 2.2.7.

5.2.5. Statistical analysis
The same linear mixed model used in section 3.2.5 was used to analyze the 18
multicellular preparations from the 3 patients used in this study.
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Table 5.1. Patients’ characteristics
Age

Gender

Diagnosis

Cardiomyopathy

65

Female

Failing

Non-ischemic

31

Female

Failing

Non-ischemic

50

Female

Failing

Non-ischemic
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5.3. Results
The results of the troponin exchange (Fig 5.2) shows that on average the
engineered troponins replaced ~80% of the native troponins in the multicellular
preparations, none of which significantly differed from the other (% exchange:
hTnC WT = 73.2 ± 15.8, hTnC L48Q = 84.7 ± 8.9, hTnC D73N = 80.0 ± 15.4,
cTnI S150D = 79.3 ± 11.9, cTnI Y26E = 84.8 ± 9.3; p > 0.05). Additionally, the
Ca2+ sensitivity data (Fig 5.3) demonstrates that in comparison to wild-type, the
Ca2+ sensitizing L48Q TnC and S150D TnI both increased (p<0.001) pCa 50 from
~5.48 to 5.84 and ~5.68, respectively. Conversely, the Ca2+desensitizing D73N
TnC and Y26E TnI both decreased (p<0.001) pCa50 to ~5.05 and ~5.29,
respectively. The Hill coefficient data also demonstrated a significant (p=0.015)
difference, which further post-hoc analysis shows is driven by the reduction in the
Hill coefficient from ~2 to ~1 in preparations containing the TnC L48Q troponin
complex (Fig 5.4). Either of the troponins had any significant impact on maximum
force (Fig 5.5), maximum power (Fig 5.6), maximum shortening velocity (Fig 5.7),
or the rate of tension recovery (Fig 5.8).
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Figure 5.2. Percentage of engineered troponins exchanged into
multicellular preparations from human myocardium.
Left) Western blot of TnT with Myc-tag and endogenous TnT to distinguish
exchanged troponin complexes from endogenous complexes. Right)
Quantification of troponin exchange. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI
Ca2+ sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation. HcTnT =
human cardiac TnT; HcTnT-myc = human cardiac TnT with Myc-tag
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Figure 5.3. Tension-pCa curve of engineered troponins. Error bars are
displayed on shapes that had multiple data points for that given pCa value.
WT = Wild-type; L48Q = TnC Ca2+ sensitizing mutation; D73N = TnC Ca2+
desensitizing mutation; S150D = TnI Ca2+ sensitizing mutation; Y26E = TnI Ca2+
desensitizing mutation

98

Figure 5.4. Engineered troponins can alter Ca2+ sensitivity in human
myocardium.
Data points represent individual multicellular preparation from n=3 patients,
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation
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Figure 5.5. Ca2+ sensitizing TnC L48Q lowers Hill coefficient.
Data points represent individual multicellular preparation from n=3 patients,
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation

100

Figure 5.6. Engineered troponins does not alter maximum isometric force.
Data points represent individual multicellular preparation from n=3 patients,
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation
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Figure 5.7. Engineered troponins do not alter maximum power.
Data points represent individual multicellular preparation from n=3 patients,
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation
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Figure 5.8. Engineered troponins do not alter maximum shortening
velocity.
Data points represent individual multicellular preparation from n=3 patients,
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation
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Figure 5.9. Engineered troponins do not alter the rate of force development,
ktr.
Data points represent individual multicellular preparation from n=3 patients,
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation
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5.4 Discussion
Unusual myofilament Ca2+ sensitivity is a common observation with several
cardiac diseases, including inherited (Hypertrophic, dilated, and restrictive)
cardiomyopathies, as well as systolic and diastolic heart failure

192,195-197.

Rodent

studies have shown that correcting the sensitivity of the myofilament to Ca2+ with
engineered troponins can correct disease-related changes in myofilament Ca2+
sensitivity and improve cardiac function

193,194.

Thus, engineered troponins may

serve as a new therapeutic strategy for treating cardiac diseases. This study
aimed to test the hypothesis that engineered troponins can be used to either
increase or decrease myofilament Ca2+ sensitivity in human myocardium.

Consistent with rodent studies 100,194, engineered troponin complexes shifted the
force-pCa relationship as predicted in human cardiac samples without altering
maximal force production (Fig 5.3). The molecular basis for the increase or
decrease in Ca2+ sensitivity as a result of the engineered TnCs and TnIs are not
fully elucidated. However, several studies have shown that the TnC L48Q
mutation increases the sensitivity of the myofilament to Ca2+ by causing an
increase in the binding of both Ca2+ and TnI to TnC 198-200. Interestingly, the TnC
L48Q mutation reduced the Hill coefficient in comparison to wild-type in the
multicellular preparations. It is unclear why the TnC L48Q mutation decreased
cooperativity in our human cardiac samples. However, consistent with our
findings, Kreutziger et al. 201 reported that myocardium from rats with the TnC
L48Q mutation demonstrated a similar reduction in the Hill coefficient when
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compared to wild-type. In their manuscript, Kreutziger and coworkers

201

suggested that the reduction in the Hill coefficient in cardiac samples with the
L48Q mutation is likely the result of a decrease in the cooperative coupling
between increased Ca2+ binding to TnC and strong cross bridge binding to actin.
It is possible that this general hypothesis can also explain the reduction in
cooperativity we see in our human cardiac samples with the TnC L48Q mutation.
Further studies are needed to test the molecular basis for the decrease in
cooperativity in rodent and human hearts with the TnC L48Q mutation.

Recently, Shettigar et al. 2017 194 showed that engineered TnC could modulate
cardiac function in healthy and diseased rodent hearts in-vivo. The results of their
study demonstrated that mice transfected with TnC L48Q before and after a
myocardial infarction had increased cardiac function (contractility, ejection
fraction, fractional shortening). More importantly, they did not see any changes in
calcium transients or saw any signs of arrhythmias, all of which have been
associated with inotropic agents. Thus, the findings of their study provided
evidence that precisely formulated troponins can tune the response of the
myofilament to Ca2+, and may serve as a novel therapy to combat heart disease.
The findings of this study would suggest that similar results may be possible in
human hearts, as engineered TnCs and TnIs were able to modulate myofilament
responsiveness to Ca2+ in human cardiac samples.
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Chapter 6
Summary
This chapter will provide an overview of the main findings reported in chapters 25. Each chapter will be divided into sections that first report the main results of
each study, followed by the clinical implications. The chapter ends with a
discussion tying together the main results of each chapter.

6.1. The Ca2+ sensitivity of right ventricular myocardium increases more
than the Ca2+ sensitivity of left ventricular myocardium in human heart
failure (chapter 2)

Summary
The results of this study presented three important results. First, human heart
failure increases the Ca2+ sensitivity of right ventricular myocardium more than
the calcium sensitivity of left ventricular myocardium. Second, this contractile
effect is likely to involve inter-ventricular differences in posttranslational
modifications to sarcomeric proteins including TnI. Third, heart failure depresses
maximum force and maximum power by similar amounts in tissue from both
ventricles.

Clinical implication
Clinically, RV dysfunction has been under-appreciated, as it was believed that
RV failure was primarily the result of impaired LV function

37.

However, several

studies have shown that left-sided and right-sided heart failure can develop
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independently of each other 39,40,42. The results of this study would suggest that
therapeutics designed to alter myosin kinetics to enhance cardiac function does
not have to be chamber specific, as mechanical parameters implicit of myosin
kinetics (maximum force, maximum power, the rate of tension recovery) did not
differ between the ventricles. However, these data imply that caution should be
taken when considering treating patients with agents that enhance myofilament
Ca2+ sensitivity, as the impact on the RV and LV may differ.

6.2. Omecamtiv mecarbil increases Ca2+ sensitivity and decreases the rate
of force development in failing human hearts (chapter 3)

Summary
The results of the omecamtiv mecarbil study demonstrated that the drug
increased calcium sensitivity and decreased the rate of tension development in a
dose-dependent manner in human cardiac samples. Additionally, the drug did not
have any significant impact on the maximally activated force. From motility
assays, (not performed as a part of this dissertation, but was a part of the paper
findings were reported in) it was proposed that OM increased calcium sensitivity
and slowed force development by increasing the amounts of myosin heads in the
strong force generating state (increased duty ratio). Additionally, the results of
the motility assay suggest that the reduction in the force development could be
the result of OM trapping a population of myosin heads in a detached or weakly
bound state with actin.

108

Clinical implication
Omecamtiv mecarbil is currently in phase II clinical trial. Phase I reports showed
that the drug increased left ventricular ejection time, ejection fraction, fractional
shortening, and stroke volume in a dose-dependent manner in healthy subjects
126,202.

In patients with stable heart failure (phase II) omecamtiv mecarbil

increased ejection time and stroke volume

143 but

did not demonstrate any of

these effects in patients with acute heart failure (phase IIb)

203.

A clinical

parameter not reported in clinical trials papers that our study suggest OM may
adversely impact is relaxation. The implications from this study are that the
higher the OM concentration, the longer the muscle will take to relax.

6.3. Para-Nitroblebbistatin reduces maximum force and calcium sensitivity
in human myocardium (chapter 4)

Summary
In permeabilized multicellular preparations from human myocardium, paraNitroblebbistatin reduced maximum force, maximum power, and calcium
sensitivity without altering the rate of force development or shortening velocity.
Results from in vitro motility assays (performed by collaborators) suggest that the
molecule can reduce force, power and calcium sensitivity by reducing the myosin
duty ratio.
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Clinical implication
Para-Nitroblebbistatin is a molecule used for research purposes, but the
mechanism by which the compound acts is of a large clinical significance, as a
drug with similar properties may be able to treat patients suffering from
hypertrophic cardiomyopathy (HCM). The molecule binds to myosin, slowing the
rate of phosphate release during the actin-myosin cycle, thus reducing the
myosin duty ratio. The findings of this study suggest that patients who suffer from
HCM may benefit from a drug with a similar mechanism of action, as these
patients often suffer from a hypercontractile heart. Recently, a small molecule
named MYK-461 was identified as a novel cardiac myosin inhibitor

183.

Like

blebbistatin, the drug was shown to reduce myosin duty ratio. Thus it may serve
as a treatment for patients suffering from HCM. The drug is currently in clinical
trial 204.

6.4. Engineered troponins modulate the Ca2+ sensitivity of the
failing human myocardium (chapter 5)

Summary
This study aimed to determine if engineered TnCs and TnIs could alter calcium
sensitivity in human myocardium. The results of the study showed that
engineered TnCs and TnIs could be used to either increase or decrease
myofilament calcium sensitivity in cardiac samples from humans without altering
myosin kinetics.
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Clinical implication
The recent advances in gene vector technology, design, and delivery modalities
have made cardiovascular gene therapy a promising option for patients suffering
from cardiac disease. Recently, a clinical trial was conducted using gene-based
therapy to correct dysfunctional sarcoplasmic/endoplasmic reticulum Ca 2+
ATPase pump activity in patients with heart failure

205.

The findings demonstrate

that gene therapy can be used to safely deliver genetic material to the heart

206,

as well as provide benefits to the patients 207. In the present study, engineered
TnCs and TnIs were able to modulate calcium sensitivity in human cardiac
samples. The clinical implication of these data is that engineered proteins along
with gene therapy have the potential to treat patients suffering from various forms
of heart disease.

6.5. Discussion
A consistent finding in each of the studies presented in this dissertation is an
alternation in myofilament calcium sensitivity. In chapter 2, we saw that calcium
sensitivity was higher in the LV of non-failing hearts, and that heart failure made
the RV was more sensitive to calcium. In chapters 3 and 4, the data showed that
the use of omecamtiv mecarbil increased myofilament calcium sensitivity
whereas para-Nitroblebbistatin decreased the sensitivity of the myofilaments to
calcium. Finally, in chapter 5, the findings demonstrated that engineered
troponins could be used to either increase or decrease myofilament calcium
sensitivity.
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As a reminder, myofilament calcium sensitivity is a concept researcher use to
simplify the complex dynamic contraction/relaxation processes of cardiac muscle
into a two variable system that describes the relationship between the
concentration of free Ca2+ ions available to bind TnC and the amount of force the
muscle generates 187. In a beating heart, changes to myofilament calcium
sensitivity are essential to its function, as an increase may lead to increased
contractility, as well as impaired relaxation. Conversely, a decrease may result in
faster relaxation rates and reduced contractility. Thus, the ability of the heart to
maintain and/or alter the sensitivity of the myofilaments to Ca 2+ is essential for
normal function. The discussion sections of chapters 2-5 have outlined the
observed changes in myofilament calcium sensitivity and described how each
could potentially alter cardiac function. Therefore, the global cardiac implications
of those findings will not be discussed any further.

A concept that has not been discussed in this dissertation is how changes in
calcium sensitivity can modulate cardiac structure. This concept has grown over
the years has studies have shown a correlation between changes in myofilament
calcium sensitivity and cardiac diseases that alter cardiac structure

62,208.

Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are
cardiac diseases commonly associated with changes in myofilament calcium
sensitivity 208. Phenotypically, HCM results in a hypertrophic heart that is
hypercontractile and has impaired relaxation; contrarily, DCM first causes an
enlargement of the left ventricular wall followed by dilation (weakening), resulting
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in systolic dysfunction (i.e., reduced ejection fraction) 209,210. The cause of HCM
and DCM are commonly mutations within sarcomeric proteins that either
increase (HCM) or decrease (DCM) myofilament calcium sensitivity

211-214.

As a

result, a paradigm as emerged that associates an increase in myofilament
calcium sensitivity with HCM and a decrease to DCM. The results of the troponin
study (chapter 5) demonstrate how mutations in sarcomeric proteins can either
increase or decrease myofilament Ca2+ sensitivity. However, the mechanism by
which changes in myofilament calcium sensitivity lead to HCM or DCM remains
unclear. The question has to how do changes in myofilament Ca2+ sensitivity
translate into cardiac disease have been asked by the field for decades, and to
date, there are no definitive answers.

Recently, a study published from the laboratory of Jeffery Molkentin asked this
very question. In their study, Davis et al. 215 mutated TnC in vivo in mice to either
increase (L48Q) or decrease (I61Q) myofilament calcium sensitivity. The results
showed that L48Q enhanced myofilament calcium sensitivity, increased fractional
shortening, slowed relaxation, and lead to a hypercontractile heart. However, the
hearts of the mice with the L48Q mutations showed no change in cardiac growth
or chamber dimensions up to 1 year of age

215.

Thus, these animals did not

display the hallmark HCM phenotype. Similar results were shown by Shettigar et
al. 194. Unlike previous studies, Davis and coworkers 215 believed that the effects
of the L48Q mutation on cardiac growth were being masked by the high
contractile state and heart rate of mouse hearts, as well as enhanced diastolic
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functions. Thus, they used the β-blocker metoprolol to try and unmask these
effects. When metoprolol was administered to the animals, the data showed that
the L48Q mutation causes an HCM like phenotype, as left ventricular wall and
septal wall thickness increased 215. The use of isoproterenol reversed these
effects the effects of metoprolol. Thus, the group concluded that the L48Q
mutation could lead to HCM like phenotype; however, in a mouse, these effects
are masked by the β-adrenergic drive which enhances relaxation and Ca2+ decay
times. They also showed that the I61Q (reduced myofilament Ca 2+ sensitivity)
mutation causes DCM in mice, which can be corrected by adding a known HCM
causing myosin mutation to increase Ca2+ sensitivity 215.

One of the key findings in the study by Davis et al.

215 was

the correction of the

I61Q-dependent dilated heart growth with the R403Q myosin mutant allele. The
results of that experiment suggested that myocytes can change their growth
profile by sensing aberrations in the magnitude and time of tension generated at
a given cytosolic Ca2+ concentration 215. The group goes on to show through a
series of experiments that the decrease in myofilament tension as a result of
altered myofilament Ca2+ binding in I61Q mice is linked to fluxes in the
sarcoplasmic Ca2+, which alters cytoplasmic Ca2+ concentration. They then
proposed that the alteration in cytoplasmic Ca2+ initiates a Ca2+dependent
signaling pathway that leads to the remodeling of the heart.

114

The proposed signaling pathway that leads to cardiac growth as a result of
changes in myofilament Ca2+ sensitivities by Davis et al. 215 is not quite clear.
Additionally, it is not universal for all mutations that alter Ca 2+ sensitivity, as they
did not see morphological changes in the L48Q mice that were not given a βblocker. Furthermore, there are mechanotransduction pathways in cardiac cells
that may also lead to cardiac remodeling 216. Further studies are needed to fully
understand how changes in myofilament Ca2+ sensitivity leads to cardiac
disease. However, the manuscript by Davis et al.

215 has

provided substantial

evidence that altered myofilament Ca2+ sensitivity can induce cardiac growth by
altering the tension generated by the myofilaments.

With the understanding that an increase or decrease in myofilament Ca 2+
sensitivity can lead to cardiac remodeling, there are implications not discussed in
the previous chapters about the Ca2+ sensitivity data that can be inferred. For
example, in the study comparing the mechanical properties of the LV and RV
(chapter 2), it may be possible that the LV is thicker than the RV and can
generate more pressure as a result of the myofilaments of the LV being more
sensitive to Ca2+. A more concerning implication of the Ca2+ sensitivity data
comes from the drugs (chapters 3 & 4) and engineered troponin (chapter 5)
studies. In the drugs and troponin studies, it was shown that small molecules and
engineered proteins could be used to either increase or decrease myofilament
Ca2+ sensitivity. Considering the tension generation idea described by Davis et
al. 215 is may be possible that continuous administration of omecamtiv mecarbil or
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MYK-461 could lead to cardiomyopathy, as these drugs can increase or
decrease myofilament tension generation respectively. Considering this theory, it
would be interesting to perform a study to see how the continuous administration
of these drugs over a long period modulate the morphology of the heart. The use
of engineered proteins to either increase or decrease myofilament Ca2+
sensitivity also pose the same possibility of causing cardiomyopathy, which was
demonstrated in the study by Davis et al.

215.

Thus caution should be taken when

considering this form of therapy.

The findings in this dissertation have provided information addressing a general
cardiac biology question (chapter 2), as well as information on how potential
therapies (chapters 3, 4, and 5) may alter the mechanical properties of human
hearts. These data will provide a significant contribution to the field, as the results
are either being revised for publication (chapter 2), being prepped for submission
(chapter 5) or have already been published (chapters 3 & 4). As it pertains to
future studies, an interesting study would be to repeat the potential therapeutics
studies (chapters 3, 4, and 5) with different myofilament lengths. This would be a
unique study, as it would address two question, 1) how does length-dependent
activation (activation of the myofilament at different lengths) influence the mode
of action for each of these therapies, and 2) how does each treatment impact
length-dependent activation.

116

References
1

Klabunde, R. Cardiovascular Physiology Concepts. (Wolters Kluwer Health, 2011).

2

Dandel, M., Lehmkuhl, H., Knosalla, C., Suramelashvili, N. & Hetzer, R. Strain and Strain
Rate Imaging by Echocardiography – Basic Concepts and Clinical Applicability. Current
Cardiology Reviews 5, 133-148, doi:10.2174/157340309788166642 (2009).

3

Edvardsen, T. & Haugaa, K. H. Imaging assessment of ventricular mechanics. Heart 97,
1349-1356, doi:10.1136/hrt.2009.184390 (2011).

4

Wang, J., Khoury, D. S., Thohan, V., Torre-Amione, G. & Nagueh, S. F. Global diastolic
strain rate for the assessment of left ventricular relaxation and filling pressures.
Circulation 115, 1376-1383, doi:10.1161/circulationaha.106.662882 (2007).

5

Kondo, R. P. et al. Comparison of contraction and calcium handling between right and
left ventricular myocytes from adult mouse heart: a role for repolarization waveform. J
Physiol 571, 131-146, doi:10.1113/jphysiol.2005.101428 (2006).

6

Janssen, P. M. L., Stull, L. B., Leppo, M. K., Altschuld, R. A. & Marbán, E. Selective
contractile dysfunction of left, not right, ventricular myocardium in the SHHF rat.
American Journal of Physiology - Heart and Circulatory Physiology 284, H772-H778,
doi:10.1152/ajpheart.01061.2001 (2003).

7

Belin, R. J. et al. Interventricular differences in myofilament function in experimental
congestive heart failure. Pflugers Arch 462, 795-809, doi:10.1007/s00424-011-1024-4
(2011).

8

McMahon, W. S., Mukherjee, R., Gillette, P. C., Crawford, F. A. & Spinale, F. G. Right and
left ventricular geometry and myocyte contractile processes with dilated
cardiomyopathy: myocyte growth and beta-adrenergic responsiveness. Cardiovascular
research 31, 314-323 (1996).

9

Rouleau, J. L., Paradis, P., Shenasa, H. & Juneau, C. Faster time to peak tension and
velocity of shortening in right versus left ventricular trabeculae and papillary muscles of
dogs. Circ Res 59, 556-561 (1986).

10

Perreault, C. L., Bing, O. H., Brooks, W. W., Ransil, B. J. & Morgan, J. P. Differential
effects of cardiac hypertrophy and failure on right versus left ventricular calcium
activation. Circ Res 67, 707-712 (1990).

11

Brooks, W. W., Bing, O. H., Blaustein, A. S. & Allen, P. D. Comparison of contractile state
and myosin isozymes of rat right and left ventricular myocardium. Journal of molecular
and cellular cardiology 19, 433-440 (1987).

12

Kleiman, R. B. & Houser, S. R. Electrophysiologic and mechanical properties of single
feline RV and LV myocytes. Journal of molecular and cellular cardiology 20, 973-982
(1988).

117

13

Harding, S. E. et al. Isolated ventricular myocytes from failing and non-failing human
heart; the relation of age and clinical status of patients to isoproterenol response.
Journal of molecular and cellular cardiology 24, 549-564 (1992).

14

Friedberg, M. K. & Redington, A. N. Right versus left ventricular failure: differences,
similarities, and interactions. Circulation 129, 1033-1044,
doi:10.1161/circulationaha.113.001375 (2014).

15

Xin, M., Olson, E. N. & Bassel-Duby, R. Mending broken hearts: cardiac development as a
basis for adult heart regeneration and repair. Nature reviews. Molecular cell biology 14,
529-541, doi:10.1038/nrm3619 (2013).

16

Harvey, R. P. Patterning the vertebrate heart. Nature reviews. Genetics 3, 544-556,
doi:10.1038/nrg843 (2002).

17

Morikawa, Y. & Cserjesi, P. Cardiac Neural Crest Expression of Hand2 Regulates Outflow
and Second Heart Field Development. Circulation Research 103, 1422-1429,
doi:10.1161/circresaha.108.180083 (2008).

18

Olson, E. N. Gene regulatory networks in the evolution and development of the heart.
Science (New York, N.Y.) 313, 1922-1927, doi:10.1126/science.1132292 (2006).

19

Buckingham, M., Meilhac, S. & Zaffran, S. Building the mammalian heart from two
sources of myocardial cells. Nature reviews. Genetics 6, 826-835, doi:10.1038/nrg1710
(2005).

20

Voelkel, N. F. et al. Right ventricular function and failure: report of a National Heart,
Lung, and Blood Institute working group on cellular and molecular mechanisms of right
heart failure. Circulation 114, 1883-1891, doi:10.1161/circulationaha.106.632208
(2006).

21

Sengupta, P. P. et al. Left ventricular structure and function: basic science for cardiac
imaging. Journal of the American College of Cardiology 48, 1988-2001,
doi:10.1016/j.jacc.2006.08.030 (2006).

22

Haddad, F., Hunt, S. A., Rosenthal, D. N. & Murphy, D. J. Right ventricular function in
cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of
the right ventricle. Circulation 117, 1436-1448, doi:10.1161/circulationaha.107.653576
(2008).

23

Martin, C. A. et al. Reduced Na(+) and higher K(+) channel expression and function
contribute to right ventricular origin of arrhythmias in Scn5a+/− mice. Open Biology 2,
120072, doi:10.1098/rsob.120072 (2012).

24

Sathish, V., Xu, A., Karmazyn, M., Sims, S. M. & Narayanan, N. Mechanistic basis of
differences in Ca2+ -handling properties of sarcoplasmic reticulum in right and left
ventricles of normal rat myocardium. American journal of physiology. Heart and
circulatory physiology 291, H88-96, doi:10.1152/ajpheart.01372.2005 (2006).

118

25

Volders, P. G. A. et al. Repolarizing K<sup>+</sup> Currents
<em>I</em><sub>TO1</sub> and <em>I</em><sub>Ks</sub> Are Larger in Right Than
Left Canine Ventricular Midmyocardium. Circulation 99, 206-210,
doi:10.1161/01.cir.99.2.206 (1999).

26

Di Diego, J. M., Sun, Z. Q. & Antzelevitch, C. I(to) and action potential notch are smaller
in left vs. right canine ventricular epicardium. The American journal of physiology 271,
H548-561 (1996).

27

Pandit, S. V. et al. Left-to-Right Ventricular Differences in I(KATP) Underlies Epicardial
Repolarization Gradient During Global Ischemia. Heart rhythm : the official journal of the
Heart Rhythm Society 8, 1732-1739, doi:10.1016/j.hrthm.2011.06.028 (2011).

28

Sivagangabalan, G. et al. Regional ion channel gene expression heterogeneity and
ventricular fibrillation dynamics in human hearts. PloS one 9, e82179,
doi:10.1371/journal.pone.0082179 (2014).

29

Clark, R. B., Bouchard, R. A., Salinas-Stefanon, E., Sanchez-Chapula, J. & Giles, W. R.
Heterogeneity of action potential waveforms and potassium currents in rat ventricle.
Cardiovascular research 27, 1795-1799 (1993).

30

Molina, C. E., Heijman, J. & Dobrev, D. Differences in Left Versus Right Ventricular
Electrophysiological Properties in Cardiac Dysfunction and Arrhythmogenesis.
Arrhythmia & electrophysiology review 5, 14-19, doi:10.15420/aer.2016.8.2 (2016).

31

Roger, V. L. Epidemiology of Heart Failure. Circulation Research 113, 646-659,
doi:10.1161/circresaha.113.300268 (2013).

32

Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure.
Nature reviews. Cardiology 8, 30-41, doi:10.1038/nrcardio.2010.165 (2011).

33

Braunwald , E. Cardiovascular Medicine at the Turn of the Millennium: Triumphs,
Concerns, and Opportunities. New England Journal of Medicine 337, 1360-1369,
doi:10.1056/nejm199711063371906 (1997).

34

Lloyd-Jones, D. et al. Heart Disease and Stroke Statistics—2010 Update. A Report From
the American Heart Association 121, e46-e215, doi:10.1161/circulationaha.109.192667
(2010).

35

Heidenreich, P. A. et al. Forecasting the future of cardiovascular disease in the United
States: a policy statement from the American Heart Association. Circulation 123, 933944, doi:10.1161/CIR.0b013e31820a55f5 (2011).

36

Mozaffarian, D. et al. Heart Disease and Stroke Statistics-2016 Update: A Report From
the American Heart Association. Circulation 133, e38-360,
doi:10.1161/cir.0000000000000350 (2016).

119

37

Dupont, M. & Tang, W. H. Right ventricular afterload and the role of nitric oxide
metabolism in left-sided heart failure. J Card Fail 19, 712-721,
doi:10.1016/j.cardfail.2013.08.004 (2013).

38

Haddad, F., Doyle, R., Murphy, D. J. & Hunt, S. A. Right ventricular function in
cardiovascular disease, part II: pathophysiology, clinical importance, and management
of right ventricular failure. Circulation 117, 1717-1731,
doi:10.1161/circulationaha.107.653584 (2008).

39

Baker, B. J., Wilen, M. M., Boyd, C. M., Dinh, H. & Franciosa, J. A. Relation of right
ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J
Cardiol 54, 596-599 (1984).

40

de Groote, P. et al. Right ventricular ejection fraction is an independent predictor of
survival in patients with moderate heart failure. Journal of the American College of
Cardiology 32, 948-954 (1998).

41

Di Salvo, T. G., Mathier, M., Semigran, M. J. & Dec, G. W. Preserved right ventricular
ejection fraction predicts exercise capacity and survival in advanced heart failure.
Journal of the American College of Cardiology 25, 1143-1153 (1995).

42

Ghio, S. et al. Independent and additive prognostic value of right ventricular systolic
function and pulmonary artery pressure in patients with chronic heart failure. Journal of
the American College of Cardiology 37, 183-188 (2001).

43

Juilliere, Y. et al. Additional predictive value of both left and right ventricular ejection
fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 18,
276-280 (1997).

44

Chatterjee, K. & Massie, B. Systolic and diastolic heart failure: differences and
similarities. Journal of cardiac failure 13, 569-576, doi:10.1016/j.cardfail.2007.04.006
(2007).

45

Aurigemma, G. P., Zile, M. R. & Gaasch, W. H. Contractile Behavior of the Left Ventricle
in Diastolic Heart Failure. With Emphasis on Regional Systolic Function 113, 296-304,
doi:10.1161/circulationaha.104.481465 (2006).

46

Aurigemma, G. P. & Gaasch, W. H. Clinical practice. Diastolic heart failure. The New
England journal of medicine 351, 1097-1105, doi:10.1056/NEJMcp022709 (2004).

47

Sjaastad, I., Wasserstrom, J. A. & Sejersted, O. M. Heart failure - a challenge to our
current concepts of excitation-contraction coupling. The Journal of Physiology 546, 3347, doi:10.1113/jphysiol.2002.034728 (2003).

48

Baicu, C. F., Zile, M. R., Aurigemma, G. P. & Gaasch, W. H. Left ventricular systolic
performance, function, and contractility in patients with diastolic heart failure.
Circulation 111, 2306-2312, doi:10.1161/01.cir.0000164273.57823.26 (2005).

120

49

McMurray, J. J. Clinical practice. Systolic heart failure. The New England journal of
medicine 362, 228-238, doi:10.1056/NEJMcp0909392 (2010).

50

Hwang, P. M. & Sykes, B. D. Targeting the sarcomere to correct muscle function. Nature
reviews. Drug discovery 14, 313-328, doi:10.1038/nrd4554 (2015).

51

Farah, C. S. & Reinach, F. C. The troponin complex and regulation of muscle contraction.
FASEB journal : official publication of the Federation of American Societies for
Experimental Biology 9, 755-767 (1995).

52

Zoghbi, M. E., Woodhead, J. L., Moss, R. L. & Craig, R. Three-dimensional structure of
vertebrate cardiac muscle myosin filaments. Proceedings of the National Academy of
Sciences 105, 2386-2390, doi:10.1073/pnas.0708912105 (2008).

53

Holmes, K. C. in Myosins: A Superfamily of Molecular Motors
Netherlands, 2008).

54

Timson, D. J. Fine tuning the myosin motor: the role of the essential light chain in
striated muscle myosin. Biochimie 85, 639-645 (2003).

55

Huxley, A. F. & Niedergerke, R. Structural changes in muscle during contraction;
interference microscopy of living muscle fibres. Nature 173, 971-973 (1954).

56

Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198-205 (2002).

57

Gordon, A. M., Homsher, E. & Regnier, M. Regulation of contraction in striated muscle.
Physiological reviews 80, 853-924 (2000).

58

Lymn, R. W. & Taylor, E. W. Mechanism of adenosine triphosphate hydrolysis by
actomyosin. Biochemistry 10, 4617-4624 (1971).

59

Geeves, M. A. & Holmes, K. C. The molecular mechanism of muscle contraction.
Advances in protein chemistry 71, 161-193, doi:10.1016/s0065-3233(04)71005-0 (2005).

60

Wulf, S. F. et al. Force-producing ADP state of myosin bound to actin. Proceedings of the
National Academy of Sciences 113, E1844-E1852, doi:10.1073/pnas.1516598113 (2016).

61

Sweeney, H. L. & Houdusse, A. Structural and functional insights into the Myosin motor
mechanism. Annual review of biophysics 39, 539-557,
doi:10.1146/annurev.biophys.050708.133751 (2010).

62

Spudich, James A. Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic
Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating
Genetic Diseases. Biophysical Journal 106, 1236-1249, doi:10.1016/j.bpj.2014.02.011
(2014).

121

35-54 (Springer

63

Shen, Y. T. et al. Improvement of cardiac function by a cardiac Myosin activator in
conscious dogs with systolic heart failure. Circulation. Heart failure 3, 522-527,
doi:10.1161/circheartfailure.109.930321 (2010).

64

Malik, F. I. et al. Cardiac myosin activation: a potential therapeutic approach for systolic
heart failure. Science (New York, N.Y.) 331, 1439-1443, doi:10.1126/science.1200113
(2011).

65

Straight, A. F. et al. Dissecting temporal and spatial control of cytokinesis with a myosin
II Inhibitor. Science (New York, N.Y.) 299, 1743-1747, doi:10.1126/science.1081412
(2003).

66

Farman, G. P. et al. Blebbistatin: use as inhibitor of muscle contraction. Pflugers Archiv :
European journal of physiology 455, 995-1005, doi:10.1007/s00424-007-0375-3 (2008).

67

Poggesi, C. & Ho, C. Y. Muscle dysfunction in hypertrophic cardiomyopathy: What is
needed to move to translation? Journal of muscle research and cell motility 35, 37-45,
doi:10.1007/s10974-014-9374-0 (2014).

68

Tang, W. et al. Modulating beta-cardiac myosin function at the molecular and tissue
levels. Frontiers in physiology 7, doi:10.3389/fphys.2016.00659 (2016).

69

Solaro, R. J., Warren, C. M. & Scruggs, S. B. Why is it important to analyze the cardiac
sarcomere subproteome? Expert review of proteomics 7, 311-314,
doi:10.1586/epr.10.15 (2010).

70

Solaro, R. J. & de Tombe, P. P. Review focus series: sarcomeric proteins as key elements
in integrated control of cardiac function. Cardiovascular research 77, 616-618,
doi:10.1093/cvr/cvn004 (2008).

71

Pawson, T. & Scott, J. D. Protein phosphorylation in signaling--50 years and counting.
Trends in biochemical sciences 30, 286-290, doi:10.1016/j.tibs.2005.04.013 (2005).

72

Solaro, R. J. et al. in Molecular Control Mechanisms in Striated Muscle Contraction (eds
R. John Solaro & Richard L. Moss) 291-327 (Springer Netherlands, 2002).

73

Kensler, R. W., Craig, R. & Moss, R. L. Phosphorylation of cardiac myosin binding protein
C releases myosin heads from the surface of cardiac thick filaments. Proceedings of the
National Academy of Sciences of the United States of America 114, E1355-e1364,
doi:10.1073/pnas.1614020114 (2017).

74

Lee, A., Oh, J. G., Gorski, P. A., Hajjar, R. J. & Kho, C. Post-translational Modifications in
Heart Failure: Small Changes, Big Impact. Heart, lung & circulation 25, 319-324,
doi:10.1016/j.hlc.2015.11.008 (2016).

75

Hamdani, N. et al. Sarcomeric dysfunction in heart failure. Cardiovascular research 77,
649-658, doi:10.1093/cvr/cvm079 (2008).

122

76

Westfall, M. V. Contribution of Post-translational Phosphorylation to Sarcomere-Linked
Cardiomyopathy Phenotypes. Front Physiol 7, 407, doi:10.3389/fphys.2016.00407
(2016).

77

Schulz, E. M. et al. Decreasing Tropomyosin Phosphorylation Rescues Tropomyosininduced Familial Hypertrophic Cardiomyopathy. The Journal of Biological Chemistry 288,
28925-28935, doi:10.1074/jbc.M113.466466 (2013).

78

Zhang, R., Zhao, J., Mandveno, A. & Potter, J. D. Cardiac troponin I phosphorylation
increases the rate of cardiac muscle relaxation. Circ Res 76, 1028-1035 (1995).

79

Streng, A. S., de Boer, D., van der Velden, J., van Dieijen-Visser, M. P. & Wodzig, W. K.
Posttranslational modifications of cardiac troponin T: an overview. Journal of molecular
and cellular cardiology 63, 47-56, doi:10.1016/j.yjmcc.2013.07.004 (2013).

80

Rosas, P. C. et al. Phosphorylation of cardiac Myosin-binding protein-C is a critical
mediator of diastolic function. Circulation. Heart failure 8, 582-594,
doi:10.1161/circheartfailure.114.001550 (2015).

81

Sadayappan, S. et al. Cardiac myosin binding protein c phosphorylation is
cardioprotective. Proceedings of the National Academy of Sciences 103, 16918-16923,
doi:10.1073/pnas.0607069103 (2006).

82

Taylor, K. A. et al. Role of the essential light chain in the activation of smooth muscle
myosin by regulatory light chain phosphorylation. Journal of structural biology 185, 375382, doi:10.1016/j.jsb.2013.12.008 (2014).

83

Szczesna, D. et al. Phosphorylation of the regulatory light chains of myosin affects Ca2+
sensitivity of skeletal muscle contraction. Journal of applied physiology (Bethesda, Md. :
1985) 92, 1661-1670, doi:10.1152/japplphysiol.00858.2001 (2002).

84

Decker, R. S. et al. Phosphorylation of contractile proteins in response to α- and βadrenergic stimulation in neonatal cardiomyocytes. Translational Research 155, 27-34,
doi:10.1016/j.trsl.2009.09.007 (2010).

85

Solaro, R. J., Henze, M. & Kobayashi, T. Integration of troponin I phosphorylation with
cardiac regulatory networks. Circ Res 112, 355-366, doi:10.1161/circresaha.112.268672
(2013).

86

Bodor, G. S. et al. Troponin I Phosphorylation in the Normal and Failing Adult Human
Heart. Circulation 96, 1495-1500, doi:10.1161/01.cir.96.5.1495 (1997).

87

Brixius, K. et al. Increased Ca2+-sensitivity of myofibrillar tension in heart failure and its
functional implication. Basic Research in Cardiology 97, I111-I117,
doi:10.1007/s003950200039 (2002).

88

Knott, A., Purcell, I. & Marston, S. In vitro Motility Analysis of Thin Filaments from Failing
and Non-failing Human Heart: Troponin from Failing Human Hearts Induces Slower

123

Filament Sliding and Higher Ca2+ Sensitivity. Journal of molecular and cellular cardiology
34, 469-482, doi:http://doi.org/10.1006/jmcc.2002.1528 (2002).
89

Kooij, V. et al. Effect of troponin I Ser23/24 phosphorylation on Ca2+-sensitivity in
human myocardium depends on the phosphorylation background. Journal of molecular
and cellular cardiology 48, 954-963, doi:10.1016/j.yjmcc.2010.01.002 (2010).

90

Messer, A. E., Jacques, A. M. & Marston, S. B. Troponin phosphorylation and regulatory
function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could
account for the contractile defect in end-stage heart failure. Journal of molecular and
cellular cardiology 42, 247-259, doi:10.1016/j.yjmcc.2006.08.017 (2007).

91

Papp, Z., van der Velden, J., Borbély, A., Édes, I. & Stienen, G. J. M. Altered myocardial
force generation in end-stage human heart failure. ESC Heart Failure 1, 160-165,
doi:10.1002/ehf2.12020 (2014).

92

van der Velden, J., de Jong, J. W., Owen, V. J., Burton, P. B. & Stienen, G. J. Effect of
protein kinase A on calcium sensitivity of force and its sarcomere length dependence in
human cardiomyocytes. Cardiovascular research 46, 487-495 (2000).

93

van der Velden, J. et al. Increased Ca2+-sensitivity of the contractile apparatus in endstage human heart failure results from altered phosphorylation of contractile proteins.
Cardiovascular research 57, 37-47 (2003).

94

Blair, C. A. et al. A Protocol for Collecting Human Cardiac Tissue for Research. Vad j 2,
doi:10.13023/vad.2016.12 (2016).

95

Haynes, P. et al. Transmural heterogeneity of cellular level power output is reduced in
human heart failure. Journal of molecular and cellular cardiology 72, 1-8,
doi:10.1016/j.yjmcc.2014.02.008 (2014).

96

Campbell, K. S. & Moss, R. L. SLControl: PC-based data acquisition and analysis for
muscle mechanics. American journal of physiology. Heart and circulatory physiology
285, H2857-2864, doi:10.1152/ajpheart.00295.2003 (2003).

97

Nixon, B. R. et al. Combined Troponin I Ser-150 and Ser-23/24 Phosphorylation Sustains
Thin Filament Ca(2+) Sensitivity and Accelerates Deactivation in an Acidic Environment().
Journal of molecular and cellular cardiology 72, 177-185,
doi:10.1016/j.yjmcc.2014.03.010 (2014).

98

Salhi, H. E. et al. Cardiac Troponin I Tyrosine 26 Phosphorylation Decreases Myofilament
Ca(2+) Sensitivity and Accelerates Deactivation. Journal of molecular and cellular
cardiology 0, 257-264, doi:10.1016/j.yjmcc.2014.09.013 (2014).

99

Bardswell, S. C. et al. Distinct sarcomeric substrates are responsible for protein kinase Dmediated regulation of cardiac myofilament Ca2+ sensitivity and cross-bridge cycling.
The Journal of biological chemistry 285, 5674-5682, doi:10.1074/jbc.M109.066456
(2010).

124

100

Salhi, H. E. et al. Myofilament Calcium Sensitivity: Mechanistic Insight into TnI Ser-23/24
and Ser-150 Phosphorylation Integration. Frontiers in physiology 7, 567,
doi:10.3389/fphys.2016.00567 (2016).

101

Wolff, M. R., Whitesell, L. F. & Moss, R. L. Calcium sensitivity of isometric tension is
increased in canine experimental heart failure. Circ Res 76, 781-789 (1995).

102

Wolff, M. R., Buck, S. H., Stoker, S. W., Greaser, M. L. & Mentzer, R. M. Myofibrillar
calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies:
role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest 98,
167-176, doi:10.1172/jci118762 (1996).

103

Zaremba, R. et al. Quantitative analysis of myofilament protein phosphorylation in small
cardiac biopsies. Proteomics. Clinical applications 1, 1285-1290,
doi:10.1002/prca.200600891 (2007).

104

Chang, A. N. et al. Constitutive phosphorylation of cardiac myosin regulatory light chain
in vivo. The Journal of biological chemistry 290, 10703-10716,
doi:10.1074/jbc.M115.642165 (2015).

105

Kampourakis, T., Sun, Y. B. & Irving, M. Myosin light chain phosphorylation enhances
contraction of heart muscle via structural changes in both thick and thin filaments.
Proceedings of the National Academy of Sciences of the United States of America 113,
E3039-3047, doi:10.1073/pnas.1602776113 (2016).

106

Copeland, O. et al. Analysis of cardiac myosin binding protein-C phosphorylation in
human heart muscle. Journal of molecular and cellular cardiology 49, 1003-1011,
doi:10.1016/j.yjmcc.2010.09.007 (2010).

107

Hamdani, N. et al. More severe cellular phenotype in human idiopathic dilated
cardiomyopathy compared to ischemic heart disease. J Muscle Res Cell Motil 31, 289301, doi:10.1007/s10974-010-9231-8 (2010).

108

Kooij, V. et al. Protein kinase C α and ε phosphorylation of troponin and myosin binding
protein C reduce Ca(2+) sensitivity in human myocardium. Basic Research in Cardiology
105, 289-300, doi:10.1007/s00395-009-0053-z (2010).

109

Mamidi, R., Gresham, K. S., Li, J. & Stelzer, J. E. Cardiac myosin binding protein-C
Ser<sup>302</sup> phosphorylation regulates cardiac β-adrenergic reserve. Science
Advances 3, doi:10.1126/sciadv.1602445 (2017).

110

Molina, C. E. et al. Interventricular Differences in β-Adrenergic Responses in the Canine
Heart: Role of Phosphodiesterases. Journal of the American Heart Association 3,
doi:10.1161/jaha.114.000858 (2014).

111

Layland, J., Solaro, R. J. & Shah, A. M. Regulation of cardiac contractile function by
troponin I phosphorylation. Cardiovascular research 66, 12-21,
doi:10.1016/j.cardiores.2004.12.022 (2005).

125

112

Swenson, A. M. et al. Omecamtiv Mecarbil Enhances the Duty Ratio of Human betaCardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force
Development in Cardiac Muscle. The Journal of biological chemistry 292, 3768-3778,
doi:10.1074/jbc.M116.748780 (2017).

113

Mosterd, A. & Hoes, A. W. Clinical epidemiology of heart failure. Heart 93, 1137-1146,
doi:10.1136/hrt.2003.025270 (2007).

114

Desai, A. S. & Stevenson, L. W. Rehospitalization for heart failure: predict or prevent?
Circulation 126, 501-506, doi:10.1161/circulationaha.112.125435 (2012).

115

Greenberg, B. Novel Therapies for Heart Failure – Where Do They Stand? –. Circulation
Journal 80, 1882-1891, doi:10.1253/circj.CJ-16-0742 (2016).

116

Rosamond, W. et al. Heart Disease and Stroke Statistics—2008 Update. A Report From
the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
117, e25-e146, doi:10.1161/circulationaha.107.187998 (2008).

117

de Tombe, P. P. Altered contractile function in heart failure. Cardiovascular research 37,
367-380 (1998).

118

Houser, S. R. & Margulies, K. B. Is depressed myocyte contractility centrally involved in
heart failure? Circ Res 92, 350-358, doi:10.1161/01.res.0000060027.40275.a6 (2003).

119

Nakayama, H. et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a
primary mediator of heart failure. The Journal of clinical investigation 117, 2431-2444,
doi:10.1172/jci31060 (2007).

120

Maron, B. J., Maron, M. S. & Semsarian, C. Genetics of hypertrophic cardiomyopathy
after 20 years: clinical perspectives. Journal of the American College of Cardiology 60,
705-715, doi:10.1016/j.jacc.2012.02.068 (2012).

121

Francis, G. S., Bartos, J. A. & Adatya, S. Inotropes. Journal of the American College of
Cardiology 63, 2069-2078, doi:10.1016/j.jacc.2014.01.016 (2014).

122

Tarone, G. et al. Targeting myocardial remodelling to develop novel therapies for heart
failure: a position paper from the Working Group on Myocardial Function of the
European Society of Cardiology. European journal of heart failure 16, 494-508,
doi:10.1002/ejhf.62 (2014).

123

Kass, D. A. & Solaro, R. J. Mechanisms and use of calcium-sensitizing agents in the failing
heart. Circulation 113, 305-315, doi:10.1161/circulationaha.105.542407 (2006).

124

Morgan, B. P. et al. Discovery of omecamtiv mecarbil the first, selective, small molecule
activator of cardiac Myosin. ACS medicinal chemistry letters 1, 472-477,
doi:10.1021/ml100138q (2010).

126

125

Starling, R. C. Cardiac Myosin Activators for the Treatment of Heart Failure. Stop Now or
Push Ahead? 67, 1456-1458, doi:10.1016/j.jacc.2016.01.038 (2016).

126

Teerlink, J. R. et al. Dose-dependent augmentation of cardiac systolic function with the
selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet
(London, England) 378, 667-675, doi:10.1016/s0140-6736(11)61219-1 (2011).

127

Greenberg, B. H. et al. Safety and tolerability of omecamtiv mecarbil during exercise in
patients with ischemic cardiomyopathy and angina. JACC. Heart failure 3, 22-29,
doi:10.1016/j.jchf.2014.07.009 (2015).

128

Moin, D. S., Sackheim, J., Hamo, C. E. & Butler, J. Cardiac Myosin Activators in Systolic
Heart Failure: More Friend than Foe? Current cardiology reports 18, 100,
doi:10.1007/s11886-016-0778-x (2016).

129

James, J. & Robbins, J. At the source: treating heart failure by altering muscle motor
function. Circ Res 109, 5-7, doi:10.1161/RES.0b013e31822765e2 (2011).

130

Teerlink, J. R. A novel approach to improve cardiac performance: cardiac myosin
activators. Heart failure reviews 14, 289-298, doi:10.1007/s10741-009-9135-0 (2009).

131

Brenner, B. & Eisenberg, E. Rate of force generation in muscle: correlation with
actomyosin ATPase activity in solution. Proceedings of the National Academy of Sciences
of the United States of America 83, 3542-3546 (1986).

132

Coureux, P. D. et al. A structural state of the myosin V motor without bound nucleotide.
Nature 425, 419-423, doi:10.1038/nature01927 (2003).

133

Garg, V. & Frishman, W. H. A new approach to inotropic therapy in the treatment of
heart failure: cardiac myosin activators in treatment of HF. Cardiology in review 21, 155159, doi:10.1097/CRD.0b013e318275889c (2013).

134

Winkelmann, D. A., Forgacs, E., Miller, M. T. & Stock, A. M. Structural basis for druginduced allosteric changes to human beta-cardiac myosin motor activity. Nature
communications 6, 7974, doi:10.1038/ncomms8974 (2015).

135

Nagy, L. et al. The novel cardiac myosin activator omecamtiv mecarbil increases the
calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle
fibres of the rat. British journal of pharmacology, doi:10.1111/bph.13235 (2015).

136

Mamidi, R., Gresham, K. S., Li, A., dos Remedios, C. G. & Stelzer, J. E. Molecular effects of
the myosin activator omecamtiv mecarbil on contractile properties of skinned
myocardium lacking cardiac myosin binding protein-C. Journal of molecular and cellular
cardiology 85, 262-272, doi:10.1016/j.yjmcc.2015.06.011 (2015).

137

O'Connell, C. B., Tyska, M. J. & Mooseker, M. S. Myosin at work: Motor adaptations for a
variety of cellular functions. Biochimica et Biophysica Acta (BBA) - Molecular Cell
Research 1773, 615-630, doi:http://dx.doi.org/10.1016/j.bbamcr.2006.06.012 (2007).

127

138

Metzger, J. M. Myosin binding-induced cooperative activation of the thin filament in
cardiac myocytes and skeletal muscle fibers. Biophys J 68, 1430-1442,
doi:10.1016/s0006-3495(95)80316-4 (1995).

139

Desai, R., Geeves, M. A. & Kad, N. M. Using Fluorescent Myosin to Directly Visualize
Cooperative Activation of Thin Filaments. Journal of Biological Chemistry 290, 19151925, doi:10.1074/jbc.M114.609743 (2015).

140

Liu, Y., White, H. D., Belknap, B., Winkelmann, D. A. & Forgacs, E. Omecamtiv Mecarbil
modulates the kinetic and motile properties of porcine beta-cardiac myosin.
Biochemistry 54, 1963-1975, doi:10.1021/bi5015166 (2015).

141

Wang, Y., Ajtai, K. & Burghardt, T. P. Analytical comparison of natural and
pharmaceutical ventricular myosin activators. Biochemistry 53, 5298-5306,
doi:10.1021/bi500730t (2014).

142

Aksel, T., Choe Yu, E., Sutton, S., Ruppel, K. M. & Spudich, J. A. Ensemble force changes
that result from human cardiac myosin mutations and a small-molecule effector. Cell
reports 11, 910-920, doi:10.1016/j.celrep.2015.04.006 (2015).

143

Cleland, J. G. et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on
cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover,
dose-ranging phase 2 trial. Lancet (London, England) 378, 676-683, doi:10.1016/s01406736(11)61126-4 (2011).

144

Tang, W. et al. Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue
Levels. Frontiers in Physiology 7, doi:10.3389/fphys.2016.00659 (2017).

145

Nag, S. et al. Contractility parameters of human β-cardiac myosin with the hypertrophic
cardiomyopathy mutation R403Q show loss of motor function. Science Advances 1,
e1500511, doi:10.1126/sciadv.1500511 (2015).

146

Kawana, M., Sarkar, S. S., Sutton, S., Ruppel, K. M. & Spudich, J. A. Biophysical properties
of human β-cardiac myosin with converter mutations that cause hypertrophic
cardiomyopathy. Science Advances 3, doi:10.1126/sciadv.1601959 (2017).

147

Niimura, H. et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of
the elderly. Circulation 105, 446-451 (2002).

148

Harvey, P. A. & Leinwand, L. A. Cellular mechanisms of cardiomyopathy. The Journal of
Cell Biology 194, 355-365, doi:10.1083/jcb.201101100 (2011).

149

Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New Perspectives on the Prevalence
of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology 65,
1249-1254, doi:10.1016/j.jacc.2015.01.019 (2015).

128

150

Marian, A. J. & Roberts, R. The molecular genetic basis for hypertrophic
cardiomyopathy. Journal of molecular and cellular cardiology 33, 655-670,
doi:10.1006/jmcc.2001.1340 (2001).

151

Captur, G. & Moon, J. C. Evolution of hypertrophic cardiomyopathy in sarcomere
mutation carriers. Heart 102, 1779-1781, doi:10.1136/heartjnl-2016-310331 (2016).

152

Maron, B. J. Hypertrophic cardiomyopathy: an important global disease. The American
journal of medicine 116, 63-65 (2004).

153

Geisterfer-Lowrance, A. A. et al. A molecular basis for familial hypertrophic
cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62,
999-1006 (1990).

154

Hernandez, O. M., Jones, M., Guzman, G. & Szczesna-Cordary, D. Myosin essential light
chain in health and disease. American journal of physiology. Heart and circulatory
physiology 292, H1643-1654, doi:10.1152/ajpheart.00931.2006 (2007).

155

Poetter, K. et al. Mutations in either the essential or regulatory light chains of myosin
are associated with a rare myopathy in human heart and skeletal muscle. Nature
genetics 13, 63-69, doi:10.1038/ng0596-63 (1996).

156

Watkins, H. et al. Mutations in the cardiac myosin binding protein-C gene on
chromosome 11 cause familial hypertrophic cardiomyopathy. Nature genetics 11, 434437, doi:10.1038/ng1295-434 (1995).

157

Nowak, K. J. et al. Mutations in the skeletal muscle alpha-actin gene in patients with
actin myopathy and nemaline myopathy. Nature genetics 23, 208-212,
doi:10.1038/13837 (1999).

158

Watkins, H. et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin
in hypertrophic cardiomyopathy. The New England journal of medicine 332, 1058-1064,
doi:10.1056/nejm199504203321603 (1995).

159

Kimura, A. et al. Mutations in the cardiac troponin I gene associated with hypertrophic
cardiomyopathy. Nature genetics 16, 379-382, doi:10.1038/ng0897-379 (1997).

160

Landstrom, A. P. et al. Molecular and functional characterization of novel hypertrophic
cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. Journal of
molecular and cellular cardiology 45, 281-288, doi:10.1016/j.yjmcc.2008.05.003 (2008).

161

Schwartz, K. & Mercadier, J.-J. Cardiac troponin T and familial hypertrophic
cardiomyopathy: an energetic affair. Journal of Clinical Investigation 112, 652-654,
doi:10.1172/JCI200319632 (2003).

162

Wang, L., Seidman, J. G. & Seidman, C. E. Narrative review: harnessing molecular
genetics for the diagnosis and management of hypertrophic cardiomyopathy. Annals of

129

internal medicine 152, 513-520, w181, doi:10.7326/0003-4819-152-8-201004200-00008
(2010).
163

Richard, P. et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum
of mutations, and implications for a molecular diagnosis strategy. Circulation 107, 22272232, doi:10.1161/01.cir.0000066323.15244.54 (2003).

164

Buvoli, M., Hamady, M., Leinwand, L. A. & Knight, R. Bioinformatics assessment of betamyosin mutations reveals myosin's high sensitivity to mutations. Trends in
cardiovascular medicine 18, 141-149, doi:10.1016/j.tcm.2008.04.001 (2008).

165

Walsh, R., Rutland, C., Thomas, R. & Loughna, S. Cardiomyopathy: a systematic review of
disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations.
Cardiology 115, 49-60, doi:10.1159/000252808 (2010).

166

Colegrave, M. & Peckham, M. Structural implications of beta-cardiac myosin heavy chain
mutations in human disease. Anatomical record (Hoboken, N.J. : 2007) 297, 1670-1680,
doi:10.1002/ar.22973 (2014).

167

Debold, E. P. et al. Hypertrophic and dilated cardiomyopathy mutations differentially
affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap
assay. American journal of physiology. Heart and circulatory physiology 293, H284-291,
doi:10.1152/ajpheart.00128.2007 (2007).

168

Chuan, P., Sivaramakrishnan, S., Ashley, Euan A. & Spudich, James A. Cell-Intrinsic
Functional Effects of the α-Cardiac Myosin Arg-403-Gln Mutation in Familial
Hypertrophic Cardiomyopathy. Biophysical Journal 102, 2782-2790,
doi:10.1016/j.bpj.2012.04.049 (2012).

169

Ho, C. Y. et al. Assessment of Diastolic Function With Doppler Tissue Imaging to Predict
Genotype in Preclinical Hypertrophic Cardiomyopathy. Circulation 105, 2992-2997,
doi:10.1161/01.cir.0000019070.70491.6d (2002).

170

Kovács, M., Tóth, J., Hetényi, C., Málnási-Csizmadia, A. & Sellers, J. R. Mechanism of
Blebbistatin Inhibition of Myosin II. Journal of Biological Chemistry 279, 35557-35563,
doi:10.1074/jbc.M405319200 (2004).

171

Ramamurthy, B., Yengo, C. M., Straight, A. F., Mitchison, T. J. & Sweeney, H. L. Kinetic
mechanism of blebbistatin inhibition of nonmuscle myosin IIb. Biochemistry 43, 1483214839, doi:10.1021/bi0490284 (2004).

172

Limouze, J., Straight, A. F., Mitchison, T. & Sellers, J. R. Specificity of blebbistatin, an
inhibitor of myosin II. Journal of Muscle Research & Cell Motility 25, 337-341,
doi:10.1007/s10974-004-6060-7 (2004).

173

Zhao, F. Q., Padron, R. & Craig, R. Blebbistatin stabilizes the helical order of myosin
filaments by promoting the switch 2 closed state. Biophys J 95, 3322-3329,
doi:10.1529/biophysj.108.137067 (2008).

130

174

Xu, S., White, H. D., Offer, G. W. & Yu, L. C. Stabilization of Helical Order in the Thick
Filaments by Blebbistatin: Further Evidence of Coexisting Multiple Conformations of
Myosin. Biophysical Journal 96, 3673-3681, doi:10.1016/j.bpj.2009.01.049 (2009).

175

Wilson, C., Naber, N., Pate, E. & Cooke, R. The myosin inhibitor blebbistatin stabilizes
the super-relaxed state in skeletal muscle. Biophys J 107, 1637-1646,
doi:10.1016/j.bpj.2014.07.075 (2014).

176

McNamara, J. W., Li, A., dos Remedios, C. G. & Cooke, R. The role of super-relaxed
myosin in skeletal and cardiac muscle. Biophysical Reviews 7, 5-14, doi:10.1007/s12551014-0151-5 (2015).

177

Dou, Y., Arlock, P. & Arner, A. Blebbistatin specifically inhibits actin-myosin interaction in
mouse cardiac muscle. American journal of physiology. Cell physiology 293, C1148-1153,
doi:10.1152/ajpcell.00551.2006 (2007).

178

Sakamoto, T., Limouze, J., Combs, C. A., Straight, A. F. & Sellers, J. R. Blebbistatin, a
myosin II inhibitor, is photoinactivated by blue light. Biochemistry 44, 584-588,
doi:10.1021/bi0483357 (2005).

179

Mikulich, A., Kavaliauskiene, S. & Juzenas, P. Blebbistatin, a myosin inhibitor, is
phototoxic to human cancer cells under exposure to blue light. Biochimica et biophysica
acta 1820, 870-877, doi:10.1016/j.bbagen.2012.04.003 (2012).

180

Kepiro, M. et al. para-Nitroblebbistatin, the non-cytotoxic and photostable myosin II
inhibitor. Angewandte Chemie (International ed. in English) 53, 8211-8215,
doi:10.1002/anie.201403540 (2014).

181

Varkuti, B. H. et al. A highly soluble, non-phototoxic, non-fluorescent blebbistatin
derivative. Scientific reports 6, 26141, doi:10.1038/srep26141 (2016).

182

Fusi, L. et al. Minimum number of myosin motors accounting for shortening velocity
under zero load in skeletal muscle. J Physiol 595, 1127-1142, doi:10.1113/jp273299
(2017).

183

Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses
hypertrophic cardiomyopathy in mice. Science (New York, N.Y.) 351, 617-621,
doi:10.1126/science.aad3456 (2016).

184

Kobayashi, T. & Solaro, R. J. Increased Ca2+ affinity of cardiac thin filaments
reconstituted with cardiomyopathy-related mutant cardiac troponin I. J Biol Chem 281,
13471-13477, doi:10.1074/jbc.M509561200 (2006).

185

Sich, N. M. et al. Effects of Actin-Myosin Kinetics on the Calcium Sensitivity of Regulated
Thin Filaments. Journal of Biological Chemistry 285, 39150-39159,
doi:10.1074/jbc.M110.142232 (2010).

131

186

Lu, Q.-W., Hinken, A. C., Patrick, S. E., Solaro, R. J. & Kobayashi, T. Phosphorylation of
Cardiac Troponin I at Protein Kinase C Site Threonine 144 Depresses Cooperative
Activation of Thin Filaments. Journal of Biological Chemistry 285, 11810-11817,
doi:10.1074/jbc.M109.055657 (2010).

187

Chung, J.-H., Biesiadecki, B. J., Ziolo, M. T., Davis, J. P. & Janssen, P. M. L. Myofilament
Calcium Sensitivity: Role in Regulation of In vivo Cardiac Contraction and Relaxation.
Frontiers in Physiology 7, doi:10.3389/fphys.2016.00562 (2016).

188

Tachampa, K. et al. Increased cross-bridge cycling kinetics after exchange of C-terminal
truncated troponin I in skinned rat cardiac muscle. J Biol Chem 283, 15114-15121,
doi:10.1074/jbc.M801636200 (2008).

189

Willott, R. H. et al. Mutations in Troponin that cause HCM, DCM AND RCM: what can we
learn about thin filament function? Journal of molecular and cellular cardiology 48, 882892, doi:10.1016/j.yjmcc.2009.10.031 (2010).

190

Sumandea, M. P., Burkart, E. M., Kobayashi, T., De Tombe, P. P. & Solaro, R. J. Molecular
and integrated biology of thin filament protein phosphorylation in heart muscle. Annals
of the New York Academy of Sciences 1015, 39-52, doi:10.1196/annals.1302.004 (2004).

191

Lou, Q., Janardhan, A. & Efimov, I. R. Remodeling of Calcium Handling in Human Heart
Failure. Advances in experimental medicine and biology 740, 1145-1174,
doi:10.1007/978-94-007-2888-2_52 (2012).

192

Periasamy, M. & Janssen, P. M. L. Molecular Basis of Diastolic Dysfunction. Heart failure
clinics 4, 13-21, doi:10.1016/j.hfc.2007.10.007 (2008).

193

Liu, B., Lee, R. S., Biesiadecki, B. J., Tikunova, S. B. & Davis, J. P. Engineered troponin C
constructs correct disease-related cardiac myofilament calcium sensitivity. J Biol Chem
287, 20027-20036, doi:10.1074/jbc.M111.334953 (2012).

194

Shettigar, V. et al. Rationally engineered Troponin C modulates in vivo cardiac function
and performance in health and disease. Nature communications 7, 10794,
doi:10.1038/ncomms10794 (2016).

195

Robinson, P., Griffiths, P. J., Watkins, H. & Redwood, C. S. Dilated and hypertrophic
cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on
the calcium affinity of cardiac thin filaments. Circ Res 101, 1266-1273,
doi:10.1161/circresaha.107.156380 (2007).

196

Westfall, M. V., Borton, A. R., Albayya, F. P. & Metzger, J. M. Myofilament calcium
sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ Res
91, 525-531 (2002).

197

Frazier, A. H., Ramirez-Correa, G. A. & Murphy, A. M. Molecular mechanisms of
sarcomere dysfunction in dilated and hypertrophic cardiomyopathy. Progress in
pediatric cardiology 31, 29-33, doi:10.1016/j.ppedcard.2010.11.006 (2011).

132

198

Tikunova, S. B. & Davis, J. P. Designing calcium-sensitizing mutations in the regulatory
domain of cardiac troponin C. J Biol Chem 279, 35341-35352,
doi:10.1074/jbc.M405413200 (2004).

199

Wang, D. et al. Structural and functional consequences of the cardiac troponin C L48Q
Ca(2+)-sensitizing mutation. Biochemistry 51, 4473-4487, doi:10.1021/bi3003007
(2012).

200

Kekenes-Huskey, P. M., Lindert, S. & McCammon, J. A. Molecular basis of calciumsensitizing and desensitizing mutations of the human cardiac troponin C regulatory
domain: a multi-scale simulation study. PLoS computational biology 8, e1002777,
doi:10.1371/journal.pcbi.1002777 (2012).

201

Kreutziger, K. L. et al. Calcium binding kinetics of troponin C strongly modulate
cooperative activation and tension kinetics in cardiac muscle. Journal of molecular and
cellular cardiology 50, 165-174, doi:10.1016/j.yjmcc.2010.10.025 (2011).

202

Liu, L. C., Dorhout, B., van der Meer, P., Teerlink, J. R. & Voors, A. A. Omecamtiv
mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert
opinion on investigational drugs 25, 117-127, doi:10.1517/13543784.2016.1123248
(2016).

203

Teerlink, J. R. et al. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility
in Acute Heart Failure. The ATOMIC-AHF Study 67, 1444-1455,
doi:10.1016/j.jacc.2016.01.031 (2016).

204

Varian, K. & Tang, W. H. W. Therapeutic Strategies Targeting Inherited
Cardiomyopathies. Current heart failure reports 14, 321-330, doi:10.1007/s11897-0170346-8 (2017).

205

Hayward, C., Banner, N. R., Morley-Smith, A., Lyon, A. R. & Harding, S. E. The Current
and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.
Human gene therapy 26, 293-304, doi:10.1089/hum.2015.018 (2015).

206

Hajjar, R. J. Potential of gene therapy as a treatment for heart failure. The Journal of
clinical investigation 123, 53-61, doi:10.1172/jci62837 (2013).

207

Greenberg, B. et al. Design of a phase 2b trial of intracoronary administration of
AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium upregulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
JACC. Heart failure 2, 84-92, doi:10.1016/j.jchf.2013.09.008 (2014).

208

Dweck, D., Hus, N. & Potter, J. D. Challenging Current Paradigms Related to
Cardiomyopathies: ARE CHANGES IN THE Ca2+ SENSITIVITY OF MYOFILAMENTS
CONTAINING CARDIAC TROPONIN C MUTATIONS (G159D AND L29Q) GOOD
PREDICTORS OF THE PHENOTYPIC OUTCOMES? Journal of Biological Chemistry 283,
33119-33128, doi:10.1074/jbc.M804070200 (2008).

133

209

McNally, E. M., Golbus, J. R. & Puckelwartz, M. J. Genetic mutations and mechanisms in
dilated cardiomyopathy. The Journal of clinical investigation 123, 19-26,
doi:10.1172/JCI62862 (2013).

210

Lan, F. et al. Abnormal Calcium Handling Properties Underlie Familial Hypertrophic
Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. Cell Stem
Cell 12, 101-113, doi:10.1016/j.stem.2012.10.010.

211

Gomes, A. V. & Potter, J. D. Molecular and cellular aspects of troponin
cardiomyopathies. Annals of the New York Academy of Sciences 1015, 214-224,
doi:10.1196/annals.1302.018 (2004).

212

Chang, A. N., Harada, K., Ackerman, M. J. & Potter, J. D. Functional consequences of
hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin. J
Biol Chem 280, 34343-34349, doi:10.1074/jbc.M505014200 (2005).

213

Karibe, A. et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin
mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to
troponin, abnormal myosin cycling, and poor prognosis. Circulation 103, 65-71 (2001).

214

Du, C. K. et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin
mutation. Circ Res 101, 185-194, doi:10.1161/circresaha.106.146670 (2007).

215

Davis, J. et al. A Tension-Based Model Distinguishes Hypertrophic versus Dilated
Cardiomyopathy. Cell 165, 1147-1159, doi:10.1016/j.cell.2016.04.002 (2016).

216

Lyon, R. C., Zanella, F., Omens, J. H. & Sheikh, F. Mechanotransduction in Cardiac
Hypertrophy and Failure. Circulation research 116, 1462-1476,
doi:10.1161/CIRCRESAHA.116.304937 (2015).

134

Vita
Cheavar A. Blair
EDUCATION:
2012-2017

University of Kentucky
Graduate Program: Physiology
Ph.D. Thesis: “The mechanical properties of non-failing and
failing human hearts.”
Advisor: Dr. Kenneth Campbell

2010-2016

Southern Illinois University Carbondale
Master of Science: Plant Biology
Master’s Thesis: “Biochemical response of Brachypodium
distachyon to ultraviolet B-radiation.”
Advisor: Dr. Andrew Wood

2004-2010

Southern Illinois University Carbondale
Bachelor of Science; Major: Biological Sciences, Minor:
Chemistry

RESEARCH EXPERIENCE:
3/2013-Present

Department of Physiology, University of Kentucky
PhD research
❖ Assessed fibrosis in samples from patients with heart
failure using histology (sectioned, stained, and analyze)
❖ Isolated RNA from cardiac samples obtained from nonfailing and failing human hearts
❖ Analyzed mRNA and miRNA data from human cardiac
samples
❖ Member of a human tissue procurement team;
experience in handling, transportation, and inventory of
human tissue

10/2012-12/2012

Department of Physiology, University of Kentucky
8-week lab rotation in the lab of Dr. Karyn Esser.
❖ Performed western blot analysis on skeletal troponin I in
mice who have had Bmal1, a key circadian rhythm gene
knocked-out.

1/2013-3/2013

Department of Physiology, University of Kentucky
8-week lab rotation in the lab of Dr. Michael Reid.
❖ Isolated, prepped and analyzed force output from the
extensor digitorum longus muscle from wild-type mice.

135

8/2010-8/2012

Department of Plant Biology, Southern Illinois University
Carbondale
Masters Research
❖ Examining the molecular, biochemical, and physiological
responses of
Brachypodium distachyon (Purple false brome) to
ultraviolet radiation
❖ Performed DNA and RNA extractions
❖ Executed several molecular and biochemical assays
❖ Completed numerous transformations and ligations
❖ Researched Panicum Virgatum (Switch grass) biofuel
capacity

TEACHING AND WORK EXPERIENCE:
1/2016 – Present Adjunct Faculty, Bluegrass Community & Technical College,
Lexington, KY. Teach Anatomy and Physiology & General Biology
8/2012 – Present Research Assistant, University of Kentucky, Lexington, KY.
Studies heart failure
8/2011-5/2012 - Teaching Assistant, Southern Illinois University, Carbondale, IL.
Taught plant biology
8/2010-8/2011 - Teaching Assistant, Southern Illinois University, Carbondale, IL.
Taught general biology
MENTORING:
10/2013-present

University of Kentucky
Mentored 15 undergraduates, 4 high school students, and 4
master’s students

5/2013-Present

Big Brother, Big Sister of the Bluegrass
Mentor to a young man name De’Montavious Smith, a high
school student.

5/2014 – Present

National Institute of Health (NIH) Bridge to the Doctorate
Mentor
Mentor 3 master’s student from Kentucky State University

COMMUNITY OUTREACH:
Volunteer: (2014) YMCA Black Achievers Program in Lexington, KY

136

❖ Help in the design of the experiments students performs during our
workshops on Saturdays. Accompany students on tours, tutor, and offer
college advice to junior and senior high school students.
Master of Ceremony: (2012) International Festival at Southern Illinois
University Carbondale
❖ Invited by the SIUC International Student Council to preside over a
community-wide showcase to highlight the cultures and traditions of the
diverse SIUC student body.
PROFESSIONAL DEVELOPMENT:
2014-Present

Graduate Student Advisory Committee for LSAMP
University of Kentucky

Serve as the graduate student advisor for the Kentucky-West Virginia Louis
Stokes Alliance for Minority Participation (LSAMP) program. Attend meetings and
conferences to enhance undergraduate minority participation in Science,
Technology, Engineering, and Mathematics (STEM) programs. As a minority in a
STEM program and the only African American male student in the department of
physiology, I offer a unique perspective on the development and implementation
of the program. I work side by side with Dr. Judy Jackson, Vice President for
Institutional Diversity to develop programs to enroll, recruit, and retain minority
students in STEM programs.
January 2016

American Physiology Society (APS) Writing and
Reviewing for Scientific Journals Course

Selected to attend the writing and reviewing for scientific journals course held in
Orlando, FL presented by APS. A four-day course where students were required
to bring a manuscript that was critiqued by former presidents of APS as well as
current editors of scientific journals. Students were taught how to properly put
together a manuscript, as well as the process for submitting, revising, and
resubmitting papers to journals. Participants were also given the opportunity to
review other members documents to understand the review process.
October 2015

Guest Speaker at Centre College

Invited to Centre College in Danville, KY to speak to a small group of minority
student in STEM majors. Shared my story on the route I took towards getting into
graduate school and answered questions.
September 2015

Student Panel at GEM GRAD Lab Symposium

Serve on a graduate student panel to answer questions about graduate school to
underrepresented undergraduate students in STEM fields.
137

July 2015

Selection Committee Member for LSAMP Program Director

Selected to serve on a six persons committee to make suggestions on who
should be the new Louis Stokes Alliance for Minority Participation (LSAMP)
program director at the University of Kentucky.
April 2015
Graduate Student Discussion Panel Member for LSAMP
Conference
One of three graduate student selected to serve on the Kentucky-West Virginia
Louis Stokes Alliance for Minority Participation (KY-WV LSAMP) miniconference. Spoke to ~100 student and attendees about my experience in
graduate school and my journey to get into graduate school. Answered questions
related to my experience and offered constructive feedback.
AWARDS & FELLOWSHIPS:
Stanford ChEM-H Post-Doc Fellowship
Awarded May 2017
Awarded a two-year $100,000 ($50,000 a year) post-doctoral fellowship to
perform research at Stanford University as a member of the Chemistry,
Engineering & Medicine for Human Health (ChEM-H) program.
Lyman T. Johnson Diversity Fellowship
Awarded April 2015
Two-year fellowship awarded to graduate student who maintains a 3.3 GPA and
contributes to the University of Kentucky’s compelling interest in diversity while
demonstrating leadership and community service. Award provides tuition as well
as a $7,500 per year stipend (15,000 total).
FASEB/MARC Travel Award
Awarded February 2016
Awarded $1850 to attend the 2016 Experimental Biology conference in San
Diego, CA.
FASEB/MARC Minority Travel Award
Awarded December 2015
Awarded $1300 to attend the American Physiological Society Professional Skills
Training Course in Orlando, FL.
Brian Harding Award
Awarded November 2015
The Brian Harding award is awarded to a member of the physiology department
that makes coming to work fun, is hard working, and pushes everyone else to do
better science. I was awarded this award because my peers felt that I displayed
these characteristics.
Biophysical Society Diversity Travel Award
Awarded November 2015
Awarded a $1000 travel award from the Biophysical Society to attend the 2016
Biophysical conference in Los Angeles, Ca.
138

PUBLICATIONS:
Swenson, A. M., Tang, W., Blair, C. A., Fetrow, C. M., Unrath, W. C., Previs, M.
J., Campbell, K. S. & Yengo, C. M. (2017). Omecamtiv Mecarbil Enhances the
Duty Ratio of Human Beta Cardiac Myosin Resulting in Increased Calcium
Sensitivity and Slowed Force Development in Cardiac Muscle. J Biol Chem, In
press. PMCID not available. PMID 28082673.
Tang W, Blair C. A., Walton S, Málnási-Csizmadia A, Campbell K, and Yengo C.
Modulating beta-cardiac myosin function at the molecular and tissue levels.
Frontiers in Physiology 7: 2016. doi: 10.3389/fphys.2016.00659
Blair, C. A., Haynes, P., Campbell, S. G., Chung, C., Mitov, M. I., Dennis, D.,
Bonnell, M. R., Hoopes, C. W., Guglin, M. & Campbell, K. S. (2016). A Protocol
for Collecting Human Cardiac Tissue for Research. VAD J 2, Article 12.
http://uknowledge.uky.edu/vad/vol12/iss11/12. PMCID PMC5199025.
Campbell K. S and Blair C. A: F1000Prime Recommendation of [Zhu X et al., J
Cell Mol Med 2013, 17(9):1173-87]. In F1000Prime, 10 Mar 2014; DOI:
10.3410/f.718098345.793489967. F1000Prime.com/718098345#eval793489967
Campbell K. S and Blair C. A: F1000Prime Recommendation of [Koshman YE et
al., J Card Fail 2013, 19(4):283-94]. In F1000Prime, 27 Aug 2013; DOI:
10.3410/f.718018238.793478149. F1000Prime.com/718018238#eval793478149
ORAL ABSTRACT PRESENTATIONS:
Biophysical Society 61ST Annual Meeting, New Orleans, LA
Blair, C. A., Davis, J. P., Biesiadecki, B., Campbell, K, S. (2017) Engineered
troponins modulate the Ca2+ sensitivity of the failing human myocardium
4th Annual Kentucky American Physiological Society (APS) Meeting,
Lexington, KY
Blair, C. A., Guglin, M., Stromberg, A., Campbell, K. S. (2016) Myocardium from
the left and right ventricles of human hearts has similar mechanical properties.
Saha Cardiovascular Research Day, Lexington, KY
Blair, C. A., Guglin, M., Stromberg, A., Campbell, K. S. (2016) Myocardium from
the left and right ventricles of human hearts has similar mechanical properties.
POSTER ABSTRACT PRESENTATIONS:
Biophysical Society 61ST Annual Meeting, New Orleans, LA
Wanjian T., Blair, C. A., Campbell, K. S., Yengo, C. M. (2017) Impact of ParaNitroblebbistatin on human beta-cardiac myosin at the molecular and tissue
levels

139

Biophysical Society 61ST Annual Meeting, New Orleans, LA
Awinda, P., Blair, C. A., Guglin, M., Campbell, K. S., Tanner, B, CW. (2017)
Maximal force increases at physiological temperature in myocardial strips from
non-failing and failing human hearts
Experimental Biology, San Diego, CA
Blair, C. A., Guglin, M., Stromberg, A., Campbell, K. S. (2016) Myocardium from
the left and right ventricles of human hearts has similar mechanical properties.
Biophysical Society 60th Annual Meeting, Los Angeles, CA
Blair, C. A., Guglin, M., Stromberg, A., Campbell, K. S. (2016) Myocardium from
the left and right ventricles of human hearts has similar mechanical properties.
Biophysical Society 60th Annual Meeting, Los Angeles, CA
Swenson, A. M., Blair, C. A., Fetrow, C., Tang, W., Kenneth, M. G., Campbell,
S., et al. (2016). Omecamtiv mecarbil enhances actin affinity and slows force
production in human beta-cardiac myosin.
Center for Muscle Biology Annual Fall Retreat, Lexington, KY
Blair, C. A., Haynes, P., Campbell, K. S., Hoopes, C. W., Sadayappan, S.,
Stromberg, A. J., Nava, K. E., Lawson, B. A., Mitov, M. I., Campbell, S. G.,
Bonnell, M. R. (2014) Transmural heterogeneity of cellular level power output is
reduced in human heart failure.
Kentucky APS Conference, Louisville, KY
Blair, C. A., Haynes, P., Chung, C. S., Nava, K. E., Lawson, B. A., Mitov, M.I.,
Campbell, S. G., Bonnell, M. R., Hoopes, C. W., Campbell, K. S. (2014) Myocyte
power output in humans with end-stage heart failure: Effects of LVAD treatment.
Center for Clinical and Translational Science Conference, University of
Kentucky
Blair, C. A., Haynes, P., Campbell, K. S., Hoopes, C. W., Sadayappan, S.,
Stromberg, A. J., Nava, K. E., Lawson, B. A., Mitov, M. I., Campbell, S. G.,
Bonnell, M. R. (2014) Transmural heterogeneity of cellular level power output is
reduced in human heart failure.
Annual plant biology research day, Southern Illinois University Carbondale
Blair, C. A. and Wood, A. (2011) Characterization of Chalcone Synthase (CHS)
and CHS-like genes in Brachypodium distachyon.

140

